<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1d3 20150301//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1d3" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="hwp">eLife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn pub-type="epub" publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">09976</article-id><article-id pub-id-type="doi">10.7554/eLife.09976</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Registered Report</subject></subj-group><subj-group subj-group-type="heading"><subject>Cancer Biology</subject></subj-group></article-categories><title-group><article-title>Registered report: RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth</article-title></title-group><contrib-group><contrib contrib-type="author" id="author-37717"><name><surname>Bhargava</surname><given-names>Ajay</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-47645"><name><surname>Pelech</surname><given-names>Steven</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" id="author-37719"><name><surname>Woodard</surname><given-names>Ben</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf3"/></contrib><contrib contrib-type="author" id="author-32802"><name><surname>Kerwin</surname><given-names>John</given-names></name><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf4"/></contrib><contrib contrib-type="author" id="author-17529"><name><surname>Maherali</surname><given-names>Nimet</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="group-author-key">group-author-id1</contrib-id><collab>Reproducibility Project: Cancer Biology</collab><xref ref-type="corresp" rid="cor1">*</xref><xref ref-type="other" rid="par-1"/><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf5"/></contrib><aff id="aff1"><label>1</label><institution>Shakti BioResearch</institution>, <addr-line><named-content content-type="city">Woodbridge</named-content></addr-line>, <country>United States</country></aff><aff id="aff2"><label>2</label><institution>Kinexus Bioinformatics Corporation</institution>, <addr-line><named-content content-type="city">Vancouver</named-content></addr-line>, <country>Canada</country></aff><aff id="aff3"><label>3</label><institution content-type="dept">Biotechnology Research and Education Program</institution>, <institution>University of Maryland</institution>, <addr-line><named-content content-type="city">College Park</named-content></addr-line>, <country>United States</country></aff><aff id="aff4"><label>4</label><institution>Harvard Stem Cell Institute</institution>, <addr-line><named-content content-type="city">Cambridge</named-content></addr-line>, <country>United States</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Davis</surname><given-names>Roger</given-names></name><role>Reviewing editor</role><aff id="aff5"><institution>Howard Hughes Medical Institute &amp; University of Massachusetts Medical School</institution>, <country>United States</country></aff></contrib></contrib-group><contrib-group><contrib contrib-type="author non-byline"><contrib-id contrib-id-type="group-author-key">group-author-id1</contrib-id><name><surname>Iorns</surname><given-names>Elizabeth</given-names></name><aff><institution>Science Exchange</institution>, <addr-line><named-content content-type="city">Palo Alto</named-content></addr-line>, <country>United States</country></aff></contrib><contrib contrib-type="author non-byline"><contrib-id contrib-id-type="group-author-key">group-author-id1</contrib-id><name><surname>Gunn</surname><given-names>William</given-names></name><aff><institution>Mendeley</institution>, <addr-line><named-content content-type="city">London</named-content></addr-line>, <country>United Kingdom</country></aff></contrib><contrib contrib-type="author non-byline"><contrib-id contrib-id-type="group-author-key">group-author-id1</contrib-id><name><surname>Tan</surname><given-names>Fraser</given-names></name><aff><institution>Science Exchange</institution>, <addr-line><named-content content-type="city">Palo Alto</named-content></addr-line>, <country>United States</country></aff></contrib><contrib contrib-type="author non-byline"><contrib-id contrib-id-type="group-author-key">group-author-id1</contrib-id><name><surname>Lomax</surname><given-names>Joelle</given-names></name><aff><institution>Science Exchange</institution>, <addr-line><named-content content-type="city">Palo Alto</named-content></addr-line>, <country>United States</country></aff></contrib><contrib contrib-type="author non-byline"><contrib-id contrib-id-type="group-author-key">group-author-id1</contrib-id><name><surname>Perfito</surname><given-names>Nicole</given-names></name><aff><institution>Science Exchange</institution>, <addr-line><named-content content-type="city">Palo Alto</named-content></addr-line>, <country>United States</country></aff></contrib><contrib contrib-type="author non-byline"><contrib-id contrib-id-type="group-author-key">group-author-id1</contrib-id><name><surname>Errington</surname><given-names>Timothy</given-names></name><aff><institution>Center for Open Science</institution>, <addr-line><named-content content-type="city">Charlottesville</named-content></addr-line>, <country>United States</country></aff></contrib></contrib-group><author-notes><corresp id="cor1"><email>fraser@scienceexchange.com</email></corresp></author-notes><pub-date date-type="pub" publication-format="electronic"><day>16</day><month>02</month><year>2016</year></pub-date><pub-date pub-type="collection"><year>2016</year></pub-date><volume>5</volume><elocation-id>e09976</elocation-id><history><date date-type="received"><day>09</day><month>07</month><year>2015</year></date><date date-type="accepted"><day>06</day><month>01</month><year>2016</year></date><fn><p><mixed-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hatzivassiliou</surname><given-names>G</given-names></name><name><surname>Song</surname><given-names>K</given-names></name><name><surname>Yen</surname><given-names>I</given-names></name><name><surname>Brandhuber</surname><given-names>BJ</given-names></name><name><surname>Anderson</surname><given-names>DJ</given-names></name><name><surname>Alvarado</surname><given-names>R</given-names></name><name><surname>Ludlam</surname><given-names>MJ</given-names></name><name><surname>Stokoe</surname><given-names>D</given-names></name><name><surname>Gloor</surname><given-names>SL</given-names></name><name><surname>Vigers</surname><given-names>G</given-names></name><name><surname>Morales</surname><given-names>T</given-names></name><name><surname>Aliagas</surname><given-names>I</given-names></name><name><surname>Liu</surname><given-names>B</given-names></name><name><surname>Sideris</surname><given-names>S</given-names></name><name><surname>Hoeflich</surname><given-names>KP</given-names></name><name><surname>Jaiswal</surname><given-names>BS</given-names></name><name><surname>Seshagiri</surname><given-names>S</given-names></name><name><surname>Koeppen</surname><given-names>H</given-names></name><name><surname>Belvin</surname><given-names>M</given-names></name><name><surname>Friedman</surname><given-names>LS</given-names></name><name><surname>Malek</surname><given-names>S</given-names></name></person-group><day>18</day><month>03</month><year>2010</year> <article-title>RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth</article-title><source>Nature</source><volume>464</volume><fpage>431</fpage><lpage>435</lpage><pub-id pub-id-type="doi">10.1038/nature08833</pub-id></mixed-citation></p></fn></history><permissions><copyright-statement>Â© 2016, Bhargava et al</copyright-statement><copyright-year>2016</copyright-year><copyright-holder>Bhargava et al</copyright-holder><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-09976-v1.pdf"/><abstract><object-id pub-id-type="doi">10.7554/eLife.09976.001</object-id><p>The <ext-link ext-link-type="uri" xlink:href="https://osf.io/e81xl/wiki/home/">Reproducibility Project: Cancer Biology</ext-link> seeks to address growing concerns about reproducibility in scientific research by conducting replications of selected experiments from a number of high-profile papers in the field of cancer biology. The papers, which were published between 2010 and 2012, were selected on the basis of <ext-link ext-link-type="uri" xlink:href="https://osf.io/e81xl/wiki/studies/">citations and Altmetric scores</ext-link> (<xref ref-type="bibr" rid="bib2">Errington et al., 2014</xref>). This Registered Report describes the proposed replication plan of key experiments from 'RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth' by Hatzivassiliou and colleagues, published in Nature in 2010 (<xref ref-type="bibr" rid="bib7">Hatzivassiliou et al., 2010</xref>). Hatzivassiliou and colleagues examined the paradoxical response of RAF-WT tumors to treatment with RAF inhibitors. The key experiments being replicated include Figure 1A, in which the original authors demonstrated that treatment of a subset of BRAF<sup>WT</sup> tumor cell lines with RAF small molecule inhibitors resulted in an increase in cell viability, Figure 2B, which reported that RAF inhibitor activation of the MAPK pathway was dependent on CRAF but not BRAF, and Figure 4A, where the dimerization of BRAF and CRAF was modulated by the RAF inhibitor PLX4720, but not GDC-0879. The Reproducibility Project: Cancer Biology is a collaboration between the <ext-link ext-link-type="uri" xlink:href="http://centerforopenscience.org/">Center for Open Science</ext-link> and <ext-link ext-link-type="uri" xlink:href="https://www.scienceexchange.com/">Science Exchange</ext-link>, and the results of the replications will be published by <italic>eLife</italic>.</p><p><bold>DOI:</bold> <ext-link ext-link-type="doi" xlink:href="10.7554/eLife.09976.001">http://dx.doi.org/10.7554/eLife.09976.001</ext-link></p></abstract><kwd-group kwd-group-type="author-keywords"><title>Author Keywords</title><kwd>methodology</kwd><kwd>Reproducibility Project: Cancer Biology</kwd><kwd>paradoxical activation</kwd><kwd>BRAF inhibitors</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research Organism</title><kwd>Human</kwd></kwd-group><funding-group><award-group id="par-1"><funding-source><institution-wrap><institution>Laura and John Arnold Foundation</institution></institution-wrap></funding-source><principal-award-recipient><institution>Reproducibility Project: Cancer Biology</institution></principal-award-recipient></award-group><funding-statement>The Reproducibility Project: Cancer Biology is funded by the Laura and John Arnold Foundation, provided to the Center for Open Science in collaboration with Science Exchange. The funder had no role in study design or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta><meta-name>elife-xml-version</meta-name><meta-value>2.5</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title>Introduction</title><p>Mutations activating the H/K/N-RAS&gt;B/C-RAF&gt;MEK1/2&gt;ERK1/2 signaling pathways are commonly found in many types of cancer, making members of this pathway promising drug targets. Several small molecule inhibitors have been created that target the three RAF isoforms. However, early observations using these drugs noted a surprising paradox; while drugs targeting CRAF were able to inhibit CRAF activity in vitro, they paradoxically activated the MEK1/2&gt;ERK1/2 signaling modules in vivo. This activation was not due to direct activation of signaling components downstream of RAF (<xref ref-type="bibr" rid="bib5">Hall-Jackson et al., 1999a</xref>; <xref ref-type="bibr" rid="bib6">1999b</xref>).</p><p>Hatzivassiliou and colleagues found that RAF inhibitors, while effective in blocking signaling in BRAF<sup>V600E</sup> mutant (MT) cancer cell lines, paradoxically increased cell proliferation in BRAF<sup>WT</sup> cancer cell lines (<xref ref-type="bibr" rid="bib7">Hatzivassiliou et al., 2010</xref>). Their findings were published along with two other reports demonstrating similar results (<xref ref-type="bibr" rid="bib8">Heidorn et al., 2010</xref>; <xref ref-type="bibr" rid="bib14">Poulikakos et al., 2010</xref>) and provided a key insight into the mechanism of paradoxical RAF activation in BRAF<sup>WT</sup> cells, showing that it depended on drug-induced dimerization of wild-type (WT) RAF isoforms, specifically CRAF.</p><p>In Figure 1A, Hatzivassiliou and colleagues treated 19 cancer cell lines, comprising 4 BRAF<sup>V600E</sup> mutant lines, 7 RAF/RAS-WT lines, and 8 KRAS-MT lines, with varying concentrations of two RAF inhibitors and calculated the IC<sub>50</sub> value for each drug in each cell line. They found that, although cancer cell lines carrying the BRAF<sup>V600E</sup> mutation were susceptible to the RAF inhibitors, BRAF<sup>WT</sup> cell lines were not. This experiment will be replicated in Protocol 1.</p><p>To elucidate whether CRAF or BRAF contributed to MEK signaling in RAF-treated KRAS-mutant cells, the authors used inducible shRNA cell lines to test whether BRAF or CRAF were necessary for the activation of MEK1/2 in HCT116 cells, which are KRAS mutant. As reported in Figure 2B, silencing CRAF reversed MEK activation upon treatment with the RAF inhibitors GDC-0879 and PLX4720. This experiment will be replicated in Protocol 2.</p><p>To test whether inhibitor priming was mediated by the inhibitorsâ conformational effects on the RAF kinase domain, the authors assayed BRAF-CRAF heterodimerization through a series of immunoprecipitation assays coupled with or without RAF inhibitors. In Figure 4A, they reported that the CRAF kinase domain forms a stable complex with the BRAF kinase domain when inhibitors are not present. However, in the presence of the RAF inhibitor PLX4720, this CRAF-BRAF heterodimer kinase domain interaction is destabilized. In the presence of DGC-0879, the CRAF-BRAF interaction is stabilized. This experiment will be replicated in Protocol 3.</p><p>Hatzivassiliouâs work was published along with two companion papers; Heidorn and colleagues showed that drugs targeting BRAF<sup>V600E</sup> caused dimerization with CRAF and pathway activation (<xref ref-type="bibr" rid="bib8">Heidorn et al., 2010</xref>), while Poulikakos and colleagues observed that paradoxical RAF activation only occurred in the context of BRAF<sup>WT</sup> (<xref ref-type="bibr" rid="bib14">Poulikakos et al., 2010</xref>). In a subsequent study, Poulikakos and colleagues showed that dimerization was a critical factor in allowing a variant of BRAF<sup>V600E</sup> to demonstrate enhanced activity as compared to BRAF<sup>V600E</sup> (<xref ref-type="bibr" rid="bib15">Poulikakos et al., 2011</xref>). Work by Joseph and colleagues confirmed the findings of Hatzivassiliou and colleagues that BRAF<sup>V600E</sup> cell lines were sensitive to treatment with the BRAF inhibitor PLX4720, while RAS mutant/BRAF<sup>WT</sup> or RAS/RAF WT cell lines were not, and that MEK1/2&gt;ERK1/2 signaling was activated in these BRAF<sup>WT</sup> lines (<xref ref-type="bibr" rid="bib11">Joseph et al., 2010</xref>). Lee and colleagues assayed a panel of BRAF<sup>V600E</sup>, NRAS mutant, or BRAF/NRAS WT cell lines by treating them with PLX4720. They observed that PLX4720 inhibited ERK signaling in BRAF<sup>V600E</sup> cells, but they did not observe paradoxical MEK1/2&gt;ERK1/2 activation in BRAF<sup>WT</sup> lines. They attributed this effect to a lower percentage of serum in their culture conditions as compared to those used in previous studies. They then examined colony formation to assess drug effects on cell survival, and saw strong growth inhibition exclusively in BRAF<sup>V600E</sup> cells (<xref ref-type="bibr" rid="bib13">Lee et al., 2010</xref>). Paradoxical activation was also observed in BRAF<sup>WT</sup> cells by Carnahan and colleagues and by Halaban and colleagues (<xref ref-type="bibr" rid="bib1">Carnahan et al., 2010</xref>; <xref ref-type="bibr" rid="bib4">Halaban et al., 2010</xref>). A year later, Kaplan and colleagues published corroborating evidence that PLX4720 paradoxically activated MEK1/2&gt;ERK1/2 signaling in BRAF<sup>WT</sup> cells. They also confirmed that silencing of CRAF abrogated this activation of MEK1/2&gt;ERK1/2 signaling (<xref ref-type="bibr" rid="bib12">Kaplan et al., 2011</xref>).</p></sec><sec id="s2" sec-type="materials|methods"><title>Materials and methods</title><p>Unless otherwise noted, all protocol information were derived from the original paper, references from the original paper, or information obtained directly from the authors. An asterisk (*) indicates data or information provided by the Reproducibility Project: Cancer Biology core team. A hashtag (#) indicates information provided by the replicating lab. All references to Figures refer to the original study.</p><sec id="s2-1"><title>Protocol 1: Assessing cell viability of a panel of cancer cell lines treated with RAF and MEK inhibitors</title><p>This protocol describes the treatment of a panel of human cancer cell lines with or without mutations in BRAF or RAS with drugs targeting RAF and MEK and assessing cell viability. This experiment is a replication of Figure 1A.</p><sec id="s2-1-1"><title>Sampling</title><list list-type="bullet"><list-item><p>This experiment will be repeated four times.<list list-type="bullet"><list-item><p>See Power calculations for details.</p></list-item></list></p></list-item><list-item><p>Each experiment consists of three cohorts:<list list-type="bullet"><list-item><p>Cohort 1: Cell lines treated with a range of concentrations of PLX4720<list list-type="bullet"><list-item><p>20 ÂµM</p></list-item><list-item><p>10 ÂµM</p></list-item><list-item><p>5 ÂµM</p></list-item><list-item><p>2.5 ÂµM</p></list-item><list-item><p>1.25 ÂµM</p></list-item><list-item><p>0.625 ÂµM</p></list-item><list-item><p>0.313 ÂµM</p></list-item><list-item><p>0.156 ÂµM</p></list-item><list-item><p>0.078 ÂµM</p></list-item></list></p></list-item><list-item><p>Cohort 2: Cell lines treated with a range of concentrations of GDC-0879<list list-type="bullet"><list-item><p>20 ÂµM</p></list-item><list-item><p>10 ÂµM</p></list-item><list-item><p>5 ÂµM</p></list-item><list-item><p>2.5 ÂµM</p></list-item><list-item><p>1.25 ÂµM</p></list-item><list-item><p>0.625 ÂµM</p></list-item><list-item><p>0.313 ÂµM</p></list-item><list-item><p>0.156 ÂµM</p></list-item><list-item><p>0.078 ÂµM</p></list-item></list></p></list-item><list-item><p>Cohort 3: Cell lines treated with a range of concentrations of PD0325901<list list-type="bullet"><list-item><p>20 ÂµM</p></list-item><list-item><p>10 ÂµM</p></list-item><list-item><p>5 ÂµM</p></list-item><list-item><p>2.5 ÂµM</p></list-item><list-item><p>1.25 ÂµM</p></list-item><list-item><p>0.625 ÂµM</p></list-item><list-item><p>0.313 ÂµM</p></list-item><list-item><p>0.156 ÂµM</p></list-item><list-item><p>0.078 ÂµM</p></list-item></list></p></list-item></list></p></list-item><list-item><p>Each cohort consists of three cell lines:<list list-type="bullet"><list-item><p>A375 cells<list list-type="bullet"><list-item><p>BRAF<sup>V600E</sup> mutant</p></list-item></list></p></list-item><list-item><p>MeWo cells<list list-type="bullet"><list-item><p>RAF<sup>WT</sup>/RAS<sup>WT</sup></p></list-item></list></p></list-item><list-item><p>HCT116<list list-type="bullet"><list-item><p>RAS mutant</p></list-item></list></p></list-item></list></p></list-item></list></sec><sec id="s2-1-2"><title>Materials and reagents</title><p><table-wrap id="tblu1" position="anchor"><table frame="hsides" rules="groups"><thead><tr><th>Reagent</th><th>Type</th><th>Manufacturer</th><th>Catalog #</th><th>Comments</th></tr></thead><tbody><tr><td>A375</td><td>Cells</td><td>ATCC</td><td>CRL-1619</td><td>DMEM + 10% FBS</td></tr><tr><td>MeWo</td><td>Cells</td><td>ATCC</td><td>HTB-65</td><td>EMEM + 10% FBS</td></tr><tr><td>HCT116</td><td>Cells</td><td>ATCC</td><td>CCL-247</td><td>McCoy's 5a Medium <break/>Modified + 10% FBS</td></tr><tr><td>PLX4720</td><td>Inhibitor</td><td>Symansis</td><td>SY-PLX4720</td><td/></tr><tr><td>PD0325901</td><td>Inhibitor</td><td>Symansis</td><td>SY-PD0325901</td><td/></tr><tr><td>GDC-0879</td><td>Inhibitor</td><td>Selleckchem</td><td>S1104</td><td>Replaces Genentech and <break/>ArrayÂ BioPharma source</td></tr><tr><td>Fluorescent plate reader</td><td>Equipment</td><td>BioTek FLx800</td><td/><td/></tr><tr><td>15-cm cell culture plates</td><td>Equipment</td><td>Corning</td><td>430599</td><td>Original unspecified</td></tr><tr><td>96-well plates</td><td>Materials</td><td>Corning</td><td>3903</td><td/></tr><tr><td>DMEM</td><td>Medium</td><td>ATCC</td><td>30â2002</td><td>Original unspecified</td></tr><tr><td>EMEM</td><td>Medium</td><td>ATCC</td><td>30â2003</td><td>Original unspecified</td></tr><tr><td>McCoy's 5a medium modified</td><td>Medium</td><td>ATCC</td><td>30â2007</td><td>Original unspecified</td></tr><tr><td>Fetal bovine serum (FBS)</td><td>Reagent</td><td>ATCC</td><td>30â2020</td><td>Original unspecified</td></tr><tr><td>DMSO</td><td>Reagent</td><td>Fisher</td><td>D128â500</td><td>Original unspecified</td></tr><tr><td>Cell Titer Glo kit</td><td>Reagent</td><td>Promega</td><td>G7570</td><td/></tr></tbody></table></table-wrap></p></sec><sec id="s2-1-3"><title>Procedure</title><p>Notes:</p><list list-type="bullet"><list-item><p>A375 cells are maintained in DMEM supplemented with 10% FBS.</p></list-item><list-item><p>MeWo cells are maintained in EMEM supplemented with 10% FBS.</p></list-item><list-item><p>HCT116 cells are maintained in McCoy's 5a Medium Modified supplemented with 10% FBS.<list list-type="bullet"><list-item><p>All cell lines are kept at 37Â°C/5% CO<sub>2</sub>.</p></list-item></list></p></list-item><list-item><p>All cell lines will be sent for STR profiling and mycoplasma testing</p></list-item></list><list list-type="order"><list-item><p>Expand cell lines as needed in 15-cm plates.</p></list-item><list-item><p>Determine range of detection of replicating labâs plate reader:<list list-type="alpha-lower"><list-item><p>Plate 500 â 1.6Â ÃÂ 10<sup>4</sup> A375, MeWo, and HCT116 cells in quadruplicate wells in a 96 well plate with 100 Âµl of appropriate medium. Incubate 5 days.<list list-type="roman-lower"><list-item><p>Plate medium alone (no cells).</p></list-item><list-item><p>500 cells/well</p></list-item><list-item><p>1000 cells/well</p></list-item><list-item><p>2000 cells/well</p></list-item><list-item><p>4000 cells/well</p></list-item><list-item><p>8000 cells/well</p></list-item><list-item><p>16,000 cells/well</p></list-item></list></p></list-item><list-item><p>Five days later measure cell viability with the Cell Titer Glo kit according to manufacturerâs instructions.<list list-type="roman-lower"><list-item><p>Plot relative luminescence to cells/well.</p></list-item><list-item><p>Use seeding density for each cell line that give sub-confluency in 5 days and where the signal is still in the linear range at the end of the assay.</p></list-item></list></p></list-item></list></p></list-item><list-item><p>Seed cells, at density determined in Step 2 above, in quadruplicate wells (technical replicates) in 96-well plates and incubate overnight. Note: Information in Steps 2 through 3 is derived from Hoeflich and colleagues (<xref ref-type="bibr" rid="bib10">Hoeflich et al., 2009</xref>).<list list-type="alpha-lower"><list-item><p>Include control wells that contain media but no cells to control for background luminescence.</p></list-item><list-item><p>Also include wells with cells that will remain untreated (no DMSO).</p></list-item></list></p></list-item><list-item><p>The next day, treat cells with varying doses of each drug diluted in DMSO first and then addÂ fresh mediaÂ (to avoid excess DMSO toxicity, keep final DMSO percentage below 0.2%).<list list-type="alpha-lower"><list-item><p>Perform serial dilutions of drugs in DMSO in a 96-well plate.<list list-type="roman-lower"><list-item><p>Drug doses (twofold dilution series, see Sampling section for concentrations)</p></list-item><list-item><p>Vehicle control (DMSO)</p></list-item></list></p></list-item><list-item><p>Further dilute compounds in fresh growth media.</p></list-item><list-item><p>Replace media in wells with new media containing appropriate drug concentrations.</p></list-item><list-item><p>d. As controls, include wells of untreated cells and wells of cells treated only with vehicle.</p></list-item></list></p></list-item><list-item><p>Incubate cells for 4 days.<list list-type="alpha-lower"><list-item><p>Do not replace media during this incubation.</p></list-item></list></p></list-item><list-item><p>Measure cell viability with the Cell Titer Glo kit according to the manufacturerâs instructions.<list list-type="alpha-lower"><list-item><p>Record luminescence.</p></list-item><list-item><p>For each treated well, subtract average background luminescence calculated from media-only wells. The background luminescence defines 0% viability (baseline).</p></list-item><list-item><p>Normalize luminescence to the average of the vehicle treated cells. The vehicle-treated cells define 100% viability (top).</p></list-item><list-item><p>Fit data to a four-parameter curve, with the top and baseline held constant at 100% and 0% each, and calculate the absolute EC<sub>50</sub> value (where the curve crosses 50% viability) for each drug treatment of each cell line.<list list-type="roman-lower"><list-item><p>Only report EC<sub>50</sub> values that can be accurately estimated. Otherwise report as &gt;20 ÂµM or &lt;0.078 ÂµM.</p></list-item></list></p></list-item></list></p></list-item><list-item><p>Repeat Steps 3â6 independently three additional times.</p></list-item></list></sec><sec id="s2-1-4"><title>Deliverables</title><list list-type="bullet"><list-item><p>Data to be collected:<list list-type="bullet"><list-item><p>All raw luminescence values</p></list-item><list-item><p>Luminescence values adjusted to compensate for background luminescence</p></list-item><list-item><p>Luminescence values normalized to vehicle treated cells.</p></list-item><list-item><p>EC<sub>50</sub> values for each cell line and each drug treatment (as seen in Figure 1A)</p></list-item></list></p></list-item></list></sec><sec id="s2-1-5"><title>Confirmatory analysis plan</title><list list-type="bullet"><list-item><p>Statistical analysis of the replication data:<list list-type="bullet"><list-item><p>n/a</p></list-item></list></p></list-item><list-item><p>Meta-analysis of original and replication attempt effect sizes:<list list-type="bullet"><list-item><p>The replication data will be presented as a mean with 95% confidence intervals and will include the original data point, calculated directly from the graph, as a single point on the same plot for comparison.</p></list-item></list></p></list-item></list></sec><sec id="s2-1-6"><title>Known differences from the original study</title><list list-type="bullet"><list-item><p>All known differences are listed in the 'Materials and reagents' section above with the originally used item listed in the comments section. All differences have the same capabilities as the original and are not expected to alter the experimental design.</p></list-item><list-item><p>While the original experiment examined nineteen cell lines, the replication will be restricted to three cell lines; A375, representing the BRAF<sup>V600E</sup> mutant lines, MeWo, representing the RAF<sup>WT</sup>/RAS<sup>WT</sup> cell lines, and HCT116, representing the RAS mutant cell lines. HCT116 is used in a subsequent experiment described in Protocol 2.</p></list-item><list-item><p>The replicating lab will plate the cells in a 96-well plate as opposed to a 384-well plate.</p></list-item></list></sec><sec id="s2-1-7"><title>Provisions for quality control</title><p>All data obtained from the experiment - raw data, data analysis, control data, and quality control data - will be made publicly available, either in the published manuscript or as an open access dataset available on the Open Science Framework (<ext-link ext-link-type="uri" xlink:href="https://osf.io/0hezb/">https://osf.io/0hezb/</ext-link>).</p><list list-type="bullet"><list-item><p>STR profiling and mycoplasma detection results</p></list-item></list></sec></sec><sec id="s2-2"><title>Protocol 2: Assessing CRAF and BRAF roles in drug-dependent activation of MEK</title><p>This protocol describes the treatment of HCT116 (KRAS-MT) cells expressing doxycycline-inducible shRNAs against <italic>BRAF</italic> and <italic>CRAF</italic>, and treatment with RAF inhibitors followed by Western blot examination of activation of MEK. This experiment is a replication of Figure 2B.</p><sec id="s2-2-1"><title>Sampling</title><list list-type="bullet"><list-item><p>This experiment will be repeated seven times for a final power of â¥80%.<list list-type="bullet"><list-item><p>The original data presented is qualitative (representative images). In order to determine an appropriate number of replicates to perform initially, we have estimated the sample sizes required based on a range of potential variance.</p></list-item><list-item><p>See Power calculations for details.</p></list-item></list></p></list-item><list-item><p>The experiment consists of two cohorts:<list list-type="bullet"><list-item><p>Cohort 1: HCT116 cells with dox-inducible shRNA against BRAF</p></list-item><list-item><p>Cohort 2: HCT116 cells with dox-inducible shRNA against CRAF</p></list-item></list></p></list-item><list-item><p>Each cohort will receive the following treatments:<list list-type="bullet"><list-item><p>No dox:<list list-type="bullet"><list-item><p>DMSO</p></list-item><list-item><p>0.1 ÂµM PLX4720</p></list-item><list-item><p>1 ÂµM PLX4720</p></list-item><list-item><p>10 ÂµM PLX4720</p></list-item></list></p></list-item><list-item><p>Dox:<list list-type="bullet"><list-item><p>DMSO</p></list-item><list-item><p>0.1 ÂµM PLX4720</p></list-item><list-item><p>1 ÂµM PLX4720</p></list-item><list-item><p>10 ÂµM PLX4720</p></list-item></list></p></list-item><list-item><p>No dox:<list list-type="bullet"><list-item><p>DMSO</p></list-item><list-item><p>0.1 ÂµM GDC-0879</p></list-item><list-item><p>1 ÂµM GDC-0879</p></list-item><list-item><p>10 ÂµM GDC-0879</p></list-item></list></p></list-item><list-item><p>Dox:<list list-type="bullet"><list-item><p>DMSO</p></list-item><list-item><p>0.1 ÂµM GDC-0879</p></list-item><list-item><p>1 ÂµM GDC-0879</p></list-item><list-item><p>0 ÂµM GDC-0879</p></list-item></list></p></list-item></list></p></list-item><list-item><p>Lysates from each treatment are probed for:<list list-type="bullet"><list-item><p>phospho-MEK 1/2</p></list-item><list-item><p>total MEK 1/2</p></list-item><list-item><p>BRAF</p></list-item><list-item><p>CRAF</p></list-item><list-item><p>Actin (additional loading control)</p></list-item></list></p></list-item></list></sec><sec id="s2-2-2"><title>Materials and reagents</title><p><table-wrap id="tblu2" position="anchor"><table frame="hsides" rules="groups"><thead><tr><th>Reagent</th><th>Type</th><th>Manufacturer</th><th>Catalog #</th><th>Comments</th></tr></thead><tbody><tr><td>HCT116 cells expressing doxycycline-inducible <break/>shRNA directed against <italic>BRAF</italic></td><td>Cells</td><td colspan="2">Provided by original authors</td><td/></tr><tr><td>HCT116 cells expressing doxycycline-inducible <break/>shRNA directed against <italic>CRAF</italic></td><td>Cells</td><td colspan="2">Provided by original authors</td><td/></tr><tr><td>Doxycycline</td><td>Drug</td><td>Alfa Aesar</td><td>J67043-AE</td><td>Original unspecified</td></tr><tr><td>PLX4720 RAF inhibitor</td><td>Drug</td><td>Symansis</td><td>SY-PLX4720</td><td/></tr><tr><td>GDC-0879</td><td>Inhibitor</td><td>Selleckchem</td><td>S1104</td><td>Replaces Genentech <break/>and Array BioPharma <break/>source</td></tr><tr><td>DMSO</td><td>Reagent</td><td>Sigma</td><td>D2650-5X5ML</td><td>Original unspecified</td></tr><tr><td>McCoy's 5a Medium</td><td>Medium</td><td>ATCC</td><td>30-2007</td><td/></tr><tr><td>Fetal bovine serum</td><td>Reagent</td><td>Seradigm</td><td>1400-500G</td><td>Original unspecified</td></tr><tr><td>15-cm cell culture plates</td><td>Materials</td><td>Corning</td><td>430599</td><td>Original unspecified</td></tr><tr><td>Protease inhibitor mixture; Complete Mini</td><td>Reagent</td><td>Roche Applied Science</td><td>04693159001</td><td/></tr><tr><td>Phosphatase inhibitor mix</td><td>Reagent</td><td>Pierce</td><td>78420</td><td/></tr><tr><td>SDS-PAGE (4â20%) Tris-Glycine</td><td>Materials</td><td>BioRad</td><td>456â1094</td><td>Original unspecified</td></tr><tr><td>Nitrocellulose membrane</td><td>Materials</td><td>BioRad</td><td>170â4158</td><td>Original unspecified</td></tr><tr><td>ECL detection reagents</td><td>Reagents</td><td>Amersham</td><td>RPN2232</td><td/></tr><tr><td>Rabbit phospho MEK (pMEK) 1/2 (Ser217/221) antibody</td><td>Antibody</td><td>Cell Signaling Technology</td><td>9121</td><td>1:1000</td></tr><tr><td>Rabbit MEK 1/2 antibody (clone 47E6)</td><td>Antibody</td><td>Cell Signaling Technology</td><td>9126</td><td>1:1000</td></tr><tr><td>Mouse anti-BRAF antibody</td><td>Antibody</td><td>Santa Cruz Biotechnology</td><td>sc-5284</td><td>1:1000</td></tr><tr><td>Goat Anti-Mouse IgG-HRP</td><td>Antibody</td><td>Pierce</td><td>31432</td><td>1:5,000â1:200,000</td></tr><tr><td>Goat Anti-Rabbit IgG-HRP</td><td>Antibody</td><td>Pierce</td><td>31460</td><td>1:5,000â1:200,000</td></tr><tr><td>Mouse anti-CRAF antibody</td><td>Antibody</td><td>BD</td><td>610151</td><td>1:1000</td></tr><tr><td>Mouse anti-Ã-actin (HRP conjugate) (clone 8H10D10)</td><td>Antibody</td><td>Cell Signaling Technology</td><td>12262</td><td>Not originally used</td></tr><tr><td>Kaleidoscope prestained standards protein ladder</td><td>Reagent</td><td>BioRad</td><td>161â0324</td><td>Original unspecified</td></tr><tr><td>4â15% Mini-PROTEAN TGX Stain-Free SDS-PAGE gel</td><td>Materials</td><td>BioRad</td><td>456â8085</td><td>Original unspecified</td></tr><tr><td>Trans-Blot Turbo Mini Nitrocellulose transfer packs</td><td>Equipment</td><td>BioRad</td><td>170â4158</td><td>Original unspecified</td></tr></tbody></table></table-wrap></p></sec><sec id="s2-2-3"><title>Procedure</title><p>Notes:</p><list list-type="bullet"><list-item><p>Some information derived from Hoeflich and colleagues (<xref ref-type="bibr" rid="bib9">Hoeflich et al., 2006</xref>).</p></list-item><list-item><p>HCT116 cells are maintained in McCoyâs 5a Medium modified supplemented with 10% FBS at 37Â°C/5% CO<sub>2</sub>.</p></list-item><list-item><p>All cells will be sent for STR profiling and mycoplasma testing.</p></list-item></list><list list-type="order"><list-item><p>Determine if concentration of doxycycline to induce knockdown of BRAF and CRAF in HCT116 cells needs to be optimized. Before beginning experiment, perform protocol details as outlined below, without drug treatment (Step 4) and only analyzing expression of BRAF, CRAF, and actin (Step 8). Perform with at least 1 well per group (with and without dox treatment for each cell line).<list list-type="alpha-lower"><list-item><p>Normalize BRAF and CRAF to actin levels.</p></list-item><list-item><p>If level of depletion is not similar to reported levels in Figure 2B, further optimize conditions, such as increasing concentration of dox.</p></list-item><list-item><p>Once conditions of knockdown are optimized, use for all replicates of experimental procedure.</p></list-item></list></p></list-item><list-item><p>Seed <sup>#</sup>5x10<sup>4</sup> cells/well in 24-well plates for treatment.<list list-type="alpha-lower"><list-item><p>Seed 16 wells per cohort.<list list-type="roman-lower"><list-item><p>8 wells will be treated with dox.</p></list-item><list-item><p>8 wells will remain untreated.</p></list-item></list></p></list-item></list></p></list-item><list-item><p>Induce shRNA expression of appropriate wells by treatment with 2 mg/ml dox for 3 days.<list list-type="alpha-lower"><list-item><p>This condition will be checked in Step 1 of this protocol and optimized if needed. Once optimized, use that condition for all replicates.</p></list-item></list></p></list-item><list-item><p>Treat appropriate cells with varying concentrations of PLX4720 or GDC-0879 for 1âhr.<list list-type="alpha-lower"><list-item><p>Treat cells with varying doses of each drug diluted in DMSO first and then fresh media added (to avoid excess DMSO toxicity, keep final DMSO percentage below 0.2%).</p></list-item><list-item><p>In each set of 8 wells (dox treated and untreated), treat as follows:<list list-type="roman-lower"><list-item><p>Well 1: DMSO</p></list-item><list-item><p>Well 2: 0.1 ÂµM PLX4720</p></list-item><list-item><p>Well 3: 1 ÂµM PLX4720</p></list-item><list-item><p>Well 4: 10 ÂµM PLX4720</p></list-item><list-item><p>Well 5: DMSO</p></list-item><list-item><p>Well 6: 0.1 ÂµM GDC-0879</p></list-item><list-item><p>Well 7: 1 ÂµM GDC-0879</p></list-item><list-item><p>Well 8: 10 ÂµM GDC-0879</p></list-item></list></p></list-item></list></p></list-item><list-item><p>Lyse cells and harvest protein:<list list-type="alpha-lower"><list-item><p>Rinse cells in ice cold PBS.</p></list-item><list-item><p>Lyse cells in ice cold lysis buffer: 0.5% NP40, 20Â mM Tris pH7.5, 137Â mM NaCl, 10% glycerol, 1 mM EDTA plus protease inhibitor mixture-complete mini, and phosphatase inhibitor mix.</p></list-item><list-item><p>Spin lysate at 12,000x<italic>g</italic> for 5âmin at 4Â°C.<list list-type="roman-lower"><list-item><p>Transfer lysate to fresh tube after spinning.</p></list-item></list></p></list-item><list-item><p>Quantify protein by the BCA method.</p></list-item></list></p></list-item><list-item><p>Separate proteins by SDS-PAGE:<list list-type="alpha-lower"><list-item><p><sup>#</sup>Adjust sample to 1.5 Âµg/ÂµL with 2X Lammeli Buffer/H<sub>2</sub>O.</p></list-item><list-item><p><sup>#</sup>Boil sample for 5 min at &gt;90Â°C.<list list-type="roman-lower"><list-item><p>Load <sup>#</sup>10â20 Âµg of protein per lane on a <sup>#</sup>4â15% SDS-PAGE gel.</p></list-item><list-item><p>Run alongside a size marker ladder.</p></list-item><list-item><p>Transfer to nitrocellulose membrane using a <sup>#</sup>Trans-Blot Turbo Mini according to the manufacturerâs instructions.<list list-type="order"><list-item><p><sup>#</sup>Run at 25 V, 1 A for 30âmin.</p></list-item><list-item><p>*Confirm protein transfer by Ponceau staining.</p></list-item></list></p></list-item></list></p></list-item></list></p></list-item><list-item><p>Block membrane in 5% non-fat dried milk in TBST (20 mM Tris pH 7.5, 136 mM NaCl, 0.1% Tween-20).</p></list-item><list-item><p>Incubate membrane at 4Â°C overnight with primary antibodies <sup>#</sup>diluted in 5% milk in TBST:<list list-type="alpha-lower"><list-item><p>Mouse anti-BRAF; 1:1000 dilution; 86 kDa</p></list-item><list-item><p>Mouse anti-CRAF; 1:1000 dilution; 74 kDa</p></list-item><list-item><p>Rabbit anti-pMEK 1/2; 1:1000 dilution; 45 kDa</p></list-item><list-item><p>Rabbit anti-total MEK 1/2; 1:1000 dilution; 45 kDa</p></list-item><list-item><p>Mouse anti-Ã-Actin-HRP; 1:1000 dilution; 42 kDa<list list-type="roman-lower"><list-item><p>Run one gel/membrane per antibody; do not strip and reprobe membranes for multiple antibodies.</p></list-item><list-item><p>Note: Actin serves as a loading control to ensure equal loading of lanes (additional).</p></list-item></list></p></list-item></list></p></list-item><list-item><p><sup>#</sup>Wash membranes 3 x 5âmin in TBST.</p></list-item><list-item><p>Incubate with HRP-conjugated secondary antibodies <sup>#</sup>diluted 1:20,000 in 5% milk in TBST for 1âhr at room temperature.</p></list-item><list-item><p>Visualize bands with ECL detection kit according to manufacturerâs protocol.<list list-type="alpha-lower"><list-item><p>Quantify band intensity.</p></list-item><list-item><p>For each drug and dose in each cell line (treated with or without dox), normalize pMEK values to total MEK values.</p></list-item></list></p></list-item><list-item><p>Repeat Steps 2â11 independently six additional times.</p></list-item></list></sec><sec id="s2-2-4"><title>Deliverables</title><list list-type="bullet"><list-item><p>Data to be collected:<list list-type="bullet"><list-item><p>Images of whole gel, including ladder, of shRNA optimization (Step 1).</p></list-item><list-item><p>Images of whole gel, including ladder (compare to Figure 2B).</p></list-item><list-item><p>Quantification of band intensities; phospho-protein levels normalized to total protein levels.</p></list-item></list></p></list-item></list></sec><sec id="s2-2-5"><title>Confirmatory analysis plan</title><list list-type="bullet"><list-item><p>Statistical analysis of the replication data:<list list-type="bullet"><list-item><p>Compare band intensities across all groups.<list list-type="bullet"><list-item><p>Four-way ANOVA (2 x 2 x 2 x 4 factorial) of the normalized pMEK values for each cell line (with or without dox), drug (PLX4720 or GDC-0879), and dose (0,Â 0.1, 1, and 10 ÂµM) followed by:<list list-type="bullet"><list-item><p>Two-way interaction contrast of normalized pMEK values from BRAF and CRAF shRNA cell lines (with or without dox) across varying doses of GDC-0879 with the following Bonferroni corrected comparisons:<list list-type="bullet"><list-item><p>BRAF shRNA cell line with dox compared to without dox (across varying doses of GDC-0879)</p></list-item><list-item><p>CRAF shRNA cell line with dox compared to without dox (across varying doses of GDC-0879)</p></list-item></list></p></list-item><list-item><p>Two-way interaction contrast of normalized pMEK values from BRAF and CRAF shRNA cell lines (with or without dox) across varying doses of PLX4720 with the following Bonferroni corrected comparisons:<list list-type="bullet"><list-item><p>BRAF shRNA cell line with dox compared to without dox (across varying doses of PLX4720)</p></list-item><list-item><p>CRAF shRNA cell line with dox compared to without dox (across varying doses of PLX4720)</p></list-item></list></p></list-item></list></p></list-item></list></p></list-item></list></p></list-item><list-item><p>Meta-analysis of original and replication attempt effect sizes:<list list-type="bullet"><list-item><p>The replication data will be presented as a mean with 95% confidence intervals and will include the original data point, calculated directly from the representative image, as a single point on the same plot for comparison.</p></list-item></list></p></list-item></list></sec><sec id="s2-2-6"><title>Known differences from the original study</title><list list-type="bullet"><list-item><p>All known differences are listed in the 'Materials and reagents' section above with the originally used item listed in the comments section. All differences have the same capabilities as the original and are not expected to alter the experimental design.</p></list-item><list-item><p>The replication attempt will use actin as an additional loading control not used in the original study.</p></list-item></list></sec><sec id="s2-2-7"><title>Provisions for quality control</title><p>All data obtained from the experiment - raw data, data analysis, control data, and quality control data - will be made publicly available, either in the published manuscript or as an open access dataset available on the Open Science Framework (<ext-link ext-link-type="uri" xlink:href="https://osf.io/0hezb/">https://osf.io/0hezb/</ext-link>).</p><list list-type="bullet"><list-item><p>STR profiling and mycoplasma detection results.</p></list-item><list-item><p>Induced shRNA knockdown conditions will be checked, and optimized if needed, prior to proceeding with the experiment.</p></list-item><list-item><p>Image of Ponceau staining confirming protein transfer.</p></list-item><list-item><p>Protein loading will be confirmed using actin.</p></list-item></list></sec></sec><sec id="s2-3"><title>Protocol 3: Biochemical heterodimerization assay with recombinant RAF proteins in the presence or absence of RAF inhibitors</title><p>This protocol describes how to perform immunoprecipitation and Western blot analysis with recombinant CRAF and BRAF kinase domains in the presence or absence of the RAF inhibitors PLX4720 or GDC-0879. Wild-type BRAF and BRAF<sup>V600E</sup> kinase domains will be tested in the presence of wild-type CRAF. This experiment is a replication of Figure 4A.</p><sec id="s2-3-1"><title>Sampling</title><list list-type="bullet"><list-item><p>This experiment will be repeated six times for a final power of â¥80%.<list list-type="bullet"><list-item><p>The original data presented are qualitative (representative images). In order to determine an appropriate number of replicates to perform initially, we have estimated the sample sizes required based on a range of potential variance. We will also determine sample size postÂ hoc.</p></list-item><list-item><p>See Power calculations for details.</p></list-item></list></p></list-item><list-item><p>Each experiment consists of two cohorts:<list list-type="bullet"><list-item><p>Cohort 1: CRAF + BRAF<sup>WT</sup></p></list-item><list-item><p>Cohort 2: CRAF + BRAF<sup>V600E</sup></p></list-item></list></p></list-item><list-item><p>Each cohort is incubated with CRAF and treated for 1âhr with:<list list-type="bullet"><list-item><p>DMSO</p></list-item><list-item><p>10 ÂµM of PLX4720</p></list-item><list-item><p>10 ÂµM GDC-0879</p></list-item><list-item><p>1 mM AMP-PCP</p></list-item></list></p></list-item><list-item><p>Include a sample of CRAF, without BRAF, treated with DMSO (negative control)</p></list-item><list-item><p>Immunoprecipitate CRAF from each sample and probe for CRAF and BRAF.</p></list-item></list></sec><sec id="s2-3-2"><title>Materials and ï»¿reagents</title><p><table-wrap id="tblu3" position="anchor"><table frame="hsides" rules="groups"><thead><tr><th>Reagent</th><th>Type</th><th>Manufacturer</th><th>Catalog #</th><th>Comments</th></tr></thead><tbody><tr><td>pFBHTc delta N 1-416 BRAF</td><td>Plasmid</td><td>MRC-PPU</td><td>DU586</td><td rowspan="2">Made at Genentech and <break/>Array BioPharma. <break/>Communication with authors.</td></tr><tr><td>pFBHTc delta N 1-416 BRAF<sup>V600E</sup></td><td>Plasmid</td><td>MRC-PPU</td><td>DU603</td></tr><tr><td>Recombinant glutathione <break/><italic>S</italic>-transferase (GST)-CRAF <break/>(Y340D/Y341D) kinase domain</td><td>Protein</td><td>Invitrogen</td><td>PV3805</td><td>Original catalog # not specified</td></tr><tr><td>Assay buffer</td><td>Chemical</td><td colspan="3" rowspan="2">Specific brand information <break/>will be leftÂ up to the <break/>discretion of the replicating <break/>lab and recorded later</td></tr><tr><td>DMSO</td><td>Chemical</td></tr><tr><td>PLX4720</td><td>Inhibitor</td><td>Symansis</td><td>SY-PLX4720</td><td/></tr><tr><td>GDC-0879</td><td>Inhibitor</td><td>Selleckchem</td><td>S1104</td><td>Replaces Genentech and Array <break/>BioPharma source</td></tr><tr><td>Adenylylmethylenediphosphonate (AMP-PCP)</td><td>Chemical</td><td>Sigma</td><td>M7510</td><td>Original catalog # not specified</td></tr><tr><td>Rabbit anti-GST</td><td>Antibody</td><td>Cell Signaling Technology</td><td>2622</td><td/></tr><tr><td>Protein A agarose beads</td><td>Chromatography</td><td>Millipore</td><td>IP02</td><td>Original catalog # not specified</td></tr><tr><td>SDS-PAGE gel</td><td>Western materials</td><td colspan="2">Prepared in replicating lab</td><td>Original unspecified</td></tr><tr><td>Precision Plus Protein All Blue Standards</td><td>Reagent</td><td>BioRad</td><td>161â0393</td><td>Original unspecified</td></tr><tr><td>Ponceau stain</td><td>Reagent</td><td>Sigma</td><td>P7170</td><td>Not originally included</td></tr><tr><td>Nitrocellulose membrane</td><td>Material</td><td>Pall Corporation</td><td>PN 66485</td><td>Original unspecified</td></tr><tr><td>Mouse anti-CRAF (clone 53)</td><td>Antibody</td><td>BD Biosciences</td><td>610151</td><td/></tr><tr><td>Mouse anti-BRAF</td><td>Antibody</td><td>Sigma</td><td>WH0000673M1</td><td/></tr><tr><td>Goat anti-mouse IgG-HRP</td><td>Antibody</td><td>Invitrogen Molecular Probes</td><td>A11029</td><td>Replaces Alexa Fluor 488 <break/>goat anti-mouseÂ IgG <break/>from Invitrogen, cat# A11029</td></tr><tr><td>ECL Plus Reagent</td><td>Detection assay</td><td>Lumigen</td><td>PS-3</td><td rowspan="2">Replaces TyphoonTM Scanner <break/>from Amersham Bioscience</td></tr><tr><td>Fluor-S Max Scanner</td><td>Instrument</td><td>BioRad</td><td/></tr></tbody></table></table-wrap></p></sec><sec id="s2-3-3"><title>Procedure</title><list list-type="order"><list-item><p>Express 6His-BRAF<sup>WT</sup> and 6His-BRAF<sup>V600E</sup> kinase domains (417â766) from pFBHTc delta N 1-416 BRAF and pFBHTc delta N 1-416 BRAF<sup>V600E</sup> vectors, respectively, using baculovirus cells, following lab standard procedures. Affinity purify proteins using a nickel column using lab standard procedures.</p></list-item><list-item><p>Add 500 nM 6His-BRAF<sup>WT</sup> kinase domain or 6His-BRAF<sup>V600E</sup> kinase domain and 500 nM GST-CRAF kinase domain to assay buffer.<list list-type="alpha-lower"><list-item><p>Assay buffer: 25 mM HEPES, pH 7.4, 10 mM MgCl<sub>2</sub>, 0.01% (v/v) Triton X-100, and 2 mM DTT.</p></list-item><list-item><p>Four samples of GST-CRAF + BRAF<sup>WT</sup></p></list-item><list-item><p>Four samples of GST-CRAF + BRAF<sup>V600E</sup></p></list-item><list-item><p>One sample with GST-CRAF alone.</p></list-item></list></p></list-item><list-item><p>Incubate samples for 1âhr at room temperature in the presence of a fixed concentration of compound or vehicle:<list list-type="alpha-lower"><list-item><p>DMSO</p></list-item><list-item><p>10 ÂµM of PLX4720</p></list-item><list-item><p>10 ÂµM GDC-0879</p></list-item><list-item><p>1 mM AMP-PCP<list list-type="roman-lower"><list-item><p>For all compounds, keep final DMSO concentration to 0.25%</p></list-item></list></p></list-item></list></p></list-item><list-item><p>Immunoprecipitate GST-CRAF proteins with rabbit anti-GST antibody and protein A agarose beads following manufacturerâs instructions.</p></list-item><list-item><p>Separate proteins by SDS-PAGE:<list list-type="alpha-lower"><list-item><p>Boil samples in SDS-Sample Buffer at 100Â°C for 5âmin.</p></list-item><list-item><p>Load samples on a SDS-PAGE gel.<list list-type="roman-lower"><list-item><p>Electrophorese all samples on gel alongside a size marker ladder.</p></list-item><list-item><p>Perform electrophoresis at 30 mA for 55âmin, monitoring the dye front until it comes off the gel.</p></list-item></list></p></list-item><list-item><p>Transfer to nitrocellulose membrane at 250 mA per gel for 1âhr.<list list-type="roman-lower"><list-item><p>*Confirm protein transfer by Ponceau staining.</p></list-item></list></p></list-item></list></p></list-item><list-item><p>Block membrane in 5% non-fat dried milk in TBST (20 mM Tris-HCl pH 7.5, 136 mM NaCl, 0.1% Tween-20) as recommended by manufacturer.</p></list-item><list-item><p>Incubate membrane at 4Â°C overnight with antibodies against:<list list-type="alpha-lower"><list-item><p>Mouse anti-CRAF; 1:1000; 66 kDa</p></list-item><list-item><p>Mouse anti-BRAF; 1:1000; 44 kDa</p></list-item></list></p></list-item><list-item><p>Incubate with secondary antibody in 1X TBS for 1âhr at room temperature as recommended by manufacturer.<list list-type="alpha-lower"><list-item><p>Rinse the membrane at least three times with TBST.</p></list-item></list></p></list-item><list-item><p>Detect secondary antibody and visualize bands with an imager.<list list-type="alpha-lower"><list-item><p>Quantify band intensity.</p></list-item><list-item><p>For each sample, normalize BRAF IP values to GST-CRAF IP values.</p></list-item><list-item><p>For each BRAF variant, normalize compound treatment to DMSO.</p></list-item></list></p></list-item><list-item><p>Repeat experiment independently five additional times.</p></list-item></list></sec><sec id="s2-3-4"><title>Deliverables</title><list list-type="bullet"><list-item><p>Data to be collected:<list list-type="bullet"><list-item><p>Full gel images with ladder positions marked</p></list-item><list-item><p>Quantification of band intensities<list list-type="bullet"><list-item><p>Raw measurements as well as normalized band intensities</p></list-item></list></p></list-item><list-item><p>Graph of mean band intensities across replicates</p></list-item></list></p></list-item></list></sec><sec id="s2-3-5"><title>Confirmatory analysis plan</title><list list-type="bullet"><list-item><p>Statistical analysis of the replication data:<list list-type="bullet"><list-item><p>Bonferonni corrected one-sample <italic>t</italic>-tests of normalized BRAF<sup>WT</sup> values (normalized to GST-CRAF and then DMSO) of the following conditions compared to 1 (DMSO):<list list-type="bullet"><list-item><p>PLX4720</p></list-item><list-item><p>GDC-0879</p></list-item><list-item><p>AMP-PCP</p></list-item></list></p></list-item><list-item><p>Bonferonni corrected one-sample <italic>t</italic>-tests of normalized BRAF<sup>V600E</sup> values (normalized to GST-CRAF and then DMSO) of the following conditions compared to 1 (DMSO):<list list-type="bullet"><list-item><p>PLX4720</p></list-item><list-item><p>GDC-0879</p></list-item><list-item><p>AMP-PCP</p></list-item></list></p></list-item></list></p></list-item><list-item><p>Meta-analysis of original and replication attempt effect sizes:<list list-type="bullet"><list-item><p>The replication data will be presented as a mean with 95% confidence intervals and will include the original data point, calculated directly from the representative image, as a single point on the same plot for comparison.</p></list-item></list></p></list-item><list-item><p>Additional exploratory analysis:<list list-type="bullet"><list-item><p>Two-way ANOVA of BRAF values (normalized to GST-CRAF) from DMSO, PLX4720, GDC-0879, or AMP-PCP treated samples for each BRAF variant incubated with GST-CRAF with the following Bonferroni corrected comparisons:<list list-type="bullet"><list-item><p>BRAF<sup>WT</sup> treated with DMSO compared to BRAF<sup>WT</sup> treated with PLX4720</p></list-item><list-item><p>BRAF<sup>WT</sup> treated with DMSO compared to BRAF<sup>WT</sup> treated with GDC-0879</p></list-item><list-item><p>BRAF<sup>WT</sup> treated with DMSO compared to BRAF<sup>WT</sup> treated with AMP-PCP</p></list-item><list-item><p>BRAF<sup>V600E</sup> treated with DMSO compared to BRAF<sup>V600E</sup> treated with PLX4720</p></list-item><list-item><p>BRAF<sup>V600E</sup> treated with DMSO compared to BRAF<sup>V600E</sup> treated with GDC-0879</p></list-item><list-item><p>BRAF<sup>V600E</sup> treated with DMSO compared to BRAF<sup>V600E</sup> treated with AMP-PCP</p></list-item></list></p></list-item></list></p></list-item></list></sec><sec id="s2-3-6"><title>Known differences from the original study</title><list list-type="bullet"><list-item><p>All known differences are listed in the 'Materials and reagents' section above with the originally used item listed in the comments section. All differences have the same capabilities as the original and are not expected to alter the experimental design.</p></list-item><list-item><p>The original data examined samples treated with AZ-628, a chemically unrelated ATP-competitive RAF inhibitor, which had a similar reported effect as GDC-0879. The replication will be restricted to examining only PLX4720 and GDC-0879, similar to the other experiments included in this replication attempt.</p></list-item><list-item><p>The replicating lab will use a modified version of their in-house Western Blot protocol with antibodies analyzed by an ECL detection system instead fluorescence based.</p></list-item></list></sec><sec id="s2-3-7"><title>Provisions for quality control</title><p>All data obtained from the experiment - raw data, data analysis, control data, and quality control data - will be made publicly available, either in the published manuscript or as an open access dataset available on the Open Science Framework (<ext-link ext-link-type="uri" xlink:href="https://osf.io/0hezb/">https://osf.io/0hezb/</ext-link>).</p><list list-type="bullet"><list-item><p>Image of Ponceau staining confirming protein transfer</p></list-item></list></sec></sec></sec><sec id="s3"><title>Power calculations</title><p>Note: for details on the full set of power calculations, see <ext-link ext-link-type="uri" xlink:href="https://osf.io/a4e75/">https://osf.io/a4e75/</ext-link>.</p><sec id="s3-1"><title>Protocol 1</title><sec id="s3-1-1"><title>Summary of original data</title><list list-type="bullet"><list-item><p>Values estimated from original publishedÂ figure.</p></list-item></list><p><table-wrap id="tblu4" position="anchor"><table frame="hsides" rules="groups"><tbody><tr><td colspan="2">Figure 1A: RAF inhibitors and MEK inhibitor</td><td>EC50Â (ÂµM)</td></tr><tr><td>A375</td><td>PLX4720</td><td>0.5</td></tr><tr><td/><td>GDC-0879</td><td>0.3</td></tr><tr><td/><td>PD0325901</td><td>&lt;0.0781</td></tr><tr><td>MeWo</td><td>PLX4720</td><td>&gt;20</td></tr><tr><td/><td>GDC-0879</td><td>&gt;20</td></tr><tr><td/><td>PD0325901</td><td>&lt;0.0781</td></tr><tr><td>HCT116</td><td>PLX4720</td><td>&gt;20</td></tr><tr><td/><td>GDC-0879</td><td>&gt;20</td></tr><tr><td/><td>PD0325901</td><td>0.18</td></tr></tbody></table></table-wrap></p></sec><sec id="s3-1-2"><title>Power calculations</title><list list-type="bullet"><list-item><p>Due to EC<sub>50</sub> values, such as PLX4720 and GDC-0879 with MeWo and HCT116 cells, unable to be determined (i.e. they are above 20 ÂµM), this replication attempt will not compare values, but instead report EC<sub>50</sub> values that can be accurately estimated and compare them to the original reported values. If unable to obtain an EC<sub>50</sub> estimate the highest or lowest dose, depending on the situation, will be reported, similar to the original report.</p></list-item></list></sec></sec><sec id="s3-2"><title>Protocol 2</title><sec id="s3-2-1"><title>Summary of original data reported in Figure 2B</title><list list-type="bullet"><list-item><p>Summary of data:<list list-type="bullet"><list-item><p>Band densities were obtained with Image Studio Lite (LiCOR) from published images.</p></list-item><list-item><p>Normalization was performed by dividing the phospho-band intensity by the total protein band intensity.</p></list-item></list></p></list-item></list><p><table-wrap id="tblu5" position="anchor"><table frame="hsides" rules="groups"><tbody><tr><td colspan="5">Figure 2B; assumed number of biological replicates = 3</td></tr><tr><td>hairpin</td><td>Dox</td><td>Drug</td><td>Dose</td><td>Normalized pMEK <break/>band density</td></tr><tr><td>shBRAF</td><td>-</td><td>GDC-0879</td><td>0</td><td>0.1453</td></tr><tr><td>shBRAF</td><td>-</td><td>GDC-0879</td><td>0.1</td><td>0.8004</td></tr><tr><td>shBRAF</td><td>-</td><td>GDC-0879</td><td>1.0</td><td>0.1263</td></tr><tr><td>shBRAF</td><td>-</td><td>GDC-0879</td><td>10.0</td><td>0.0245</td></tr><tr><td>shBRAF</td><td>+</td><td>GDC-0879</td><td>0</td><td>0.0457</td></tr><tr><td>shBRAF</td><td>+</td><td>GDC-0879</td><td>0.1</td><td>0.6477</td></tr><tr><td>shBRAF</td><td>+</td><td>GDC-0879</td><td>1.0</td><td>0.1485</td></tr><tr><td>shBRAF</td><td>+</td><td>GDC-0879</td><td>10.0</td><td>0.0115</td></tr><tr><td>shBRAF</td><td>-</td><td>PLX4720</td><td>0</td><td>0.0795</td></tr><tr><td>shBRAF</td><td>-</td><td>PLX472</td><td>0.1</td><td>0.1615</td></tr><tr><td>shBRAF</td><td>-</td><td>PLX472</td><td>1.0</td><td>0.7760</td></tr><tr><td>shBRAF</td><td>-</td><td>PLX472</td><td>10.0</td><td>1.0721</td></tr><tr><td>shBRAF</td><td>+</td><td>PLX472</td><td>0</td><td>0.0861</td></tr><tr><td>shBRAF</td><td>+</td><td>PLX472</td><td>0.1</td><td>0.1388</td></tr><tr><td>shBRAF</td><td>+</td><td>PLX472</td><td>1.0</td><td>0.4522</td></tr><tr><td>shBRAF</td><td>+</td><td>PLX472</td><td>10.0</td><td>0.9831</td></tr><tr><td>shCRAF</td><td>-</td><td>GDC-0879</td><td>0</td><td>0.2121</td></tr><tr><td>shCRAF</td><td>-</td><td>GDC-0879</td><td>0.1</td><td>0.7038</td></tr><tr><td>shCRAF</td><td>-</td><td>GDC-0879</td><td>1.0</td><td>0.1554</td></tr><tr><td>shCRAF</td><td>-</td><td>GDC-0879</td><td>10.0</td><td>0.0239</td></tr><tr><td>shCRAF</td><td>+</td><td>GDC-0879</td><td>0</td><td>0.1005</td></tr><tr><td>shCRAF</td><td>+</td><td>GDC-0879</td><td>0.1</td><td>0.1896</td></tr><tr><td>shCRAF</td><td>+</td><td>GDC-0879</td><td>1.0</td><td>0.0933</td></tr><tr><td>shCRAF</td><td>+</td><td>GDC-0879</td><td>10.0</td><td>0.0315</td></tr><tr><td>shCRAF</td><td>-</td><td>PLX4720</td><td>0</td><td>0.4166</td></tr><tr><td>shCRAF</td><td>-</td><td>PLX472</td><td>0.1</td><td>0.7469</td></tr><tr><td>shCRAF</td><td>-</td><td>PLX472</td><td>1.0</td><td>1.1387</td></tr><tr><td>shCRAF</td><td>-</td><td>PLX472</td><td>10.0</td><td>1.2976</td></tr><tr><td>shCRAF</td><td>+</td><td>PLX472</td><td>0</td><td>0.2945</td></tr><tr><td>shCRAF</td><td>+</td><td>PLX472</td><td>0.1</td><td>0.2449</td></tr><tr><td>shCRAF</td><td>+</td><td>PLX472</td><td>1.0</td><td>0.2983</td></tr><tr><td>shCRAF</td><td>+</td><td>PLX472</td><td>10.0</td><td>0.2729</td></tr></tbody></table></table-wrap></p><p>The original data does not indicate the error associated with multiple biological replicates. To identify a suitable sample size, power calculations were performed using different levels of relative variance using the values quantified from the reported image as the mean. At each level of variance the effect size was estimated and used to calculate the needed sample size to achieve at least 80% power with the indicated alpha error. The achieved power is reported.</p></sec><sec id="s3-2-2"><title>Test family</title><list list-type="bullet"><list-item><p>Four-way ANOVA: Fixed effects, special, main effects and interactions, alpha error = 0.05</p></list-item></list></sec><sec id="s3-2-3"><title>Power calculations</title><list list-type="bullet"><list-item><p>Performed with G*Power software, version 3.1.7 (<xref ref-type="bibr" rid="bib3">Faul et al., 2007</xref>).</p></list-item><list-item><p>ANOVA F test statistic and partial Î·<sup>2</sup>Â performed with R software, version 3.2.2 (<xref ref-type="bibr" rid="bib16">R Core Team, 2015</xref>).<list list-type="bullet"><list-item><p>For a given relative variance, 10,000 simulations were run and the F statistic and partial Î·<sup>2</sup> was calculated for each simulated data set.</p></list-item></list></p></list-item></list><p><table-wrap id="tblu6" position="anchor"><table frame="hsides" rules="groups"><thead><tr><th>Groups</th><th>Variance estimate</th><th>F test statistic F(1,64) <break/>(shRNA, Dox, <break/>Drug interaction)</th><th>Partial Î·<sup>2</sup></th><th>Effect size <italic>f</italic></th><th>A priori power</th><th>Total sample <break/>size <break/>(32 groups)</th></tr></thead><tbody><tr><td rowspan="4">Normalized pMEK <break/>in shBRAF or <break/>shCRAF cells treated <break/>with orÂ without Dox <break/>and varyingÂ doses <break/>of GDC-0879Â or <break/>PLX4720</td><td>2%</td><td>2513.61</td><td>0.97245</td><td>5.94063</td><td>99.9%</td><td>96</td></tr><tr><td>15%</td><td>45.6115</td><td>0.39616</td><td>0.80999</td><td>99.9%</td><td>96</td></tr><tr><td>28%</td><td>13.8318</td><td>0.16726</td><td>0.44817</td><td>99.1%</td><td>96</td></tr><tr><td>40%</td><td>7.3203</td><td>0.09650</td><td>0.32681</td><td>88.4%</td><td>96</td></tr></tbody></table></table-wrap></p></sec><sec id="s3-2-4"><title>Test family</title><list list-type="bullet"><list-item><p>ANOVA: Fixed effects, special, main effects and interactions, alpha error = 0.05 for two-way interaction contrast.</p></list-item></list></sec><sec id="s3-2-5"><title>Power calculations</title><list list-type="bullet"><list-item><p>Performed with G*Power software, version 3.1.7 (<xref ref-type="bibr" rid="bib3">Faul et al., 2007</xref>).</p></list-item></list><p><table-wrap id="tblu7" position="anchor"><table frame="hsides" rules="groups"><thead><tr><th>Groups</th><th>Variance estimate</th><th>F test statistic <break/>F(1,64) <break/>(shRNA, Dox)</th><th>Partial Î·<sup>2</sup></th><th>Effect size <italic>f</italic></th><th>A priori power</th><th>Total sample <break/>size <break/>(32 groups)</th></tr></thead><tbody><tr><td rowspan="4">Normalized pMEK <break/>in shBRAF or shCRAF <break/>cells treated with or <break/>without Dox across <break/>varyingÂ doses of <break/>GDC-0879</td><td>2%</td><td>327.18</td><td>0.83639</td><td>2.26101</td><td>99.9%</td><td>96</td></tr><tr><td>15%</td><td>5.81651</td><td>0.08331</td><td>0.30147</td><td>82.9%</td><td>96</td></tr><tr><td>28%</td><td>1.66928</td><td>0.02542</td><td>0.16150</td><td>82.1%</td><td>320</td></tr><tr><td>40%</td><td>0.81795</td><td>0.01262</td><td>0.11305</td><td>81.5%</td><td>640</td></tr><tr><td rowspan="4">Normalized pMEK <break/>in shBRAF or <break/>shCRAF cells treated <break/>with orÂ without Dox <break/>acrossÂ varying doses <break/>ofÂ PLX4720</td><td>2%</td><td>7267.4</td><td>0.99127</td><td>10.6561</td><td>99.9%</td><td>96</td></tr><tr><td>15%</td><td>129.198</td><td>0.66873</td><td>1.42082</td><td>99.9%</td><td>96</td></tr><tr><td>28%</td><td>37.0786</td><td>0.36683</td><td>0.76115</td><td>99.9%</td><td>96</td></tr><tr><td>40%</td><td>18.1685</td><td>0.22111</td><td>0.53281</td><td>99.9%</td><td>96</td></tr></tbody></table></table-wrap></p></sec><sec id="s3-2-6"><title>Test family</title><list list-type="bullet"><list-item><p>ANOVA: Fixed effects, special, main effects and interactions, Bonferroniâs correction, alpha error = 0.025 for contrasts within each drug type</p></list-item></list></sec><sec id="s3-2-7"><title>Power calculations</title><list list-type="bullet"><list-item><p>Performed with G*Power software, version 3.1.7 (<xref ref-type="bibr" rid="bib3">Faul et al., 2007</xref>).</p></list-item></list><p><table-wrap id="tblu8" position="anchor"><table frame="hsides" rules="groups"><thead><tr><th>Drug</th><th>Group 1 <break/>across dose</th><th>Group 2 <break/>across dose</th><th>Variance <break/>estimate</th><th>Effect <break/>size <italic>f</italic></th><th>A priori <break/>power</th><th>Samples <break/>per group</th></tr></thead><tbody><tr><td rowspan="8">GDC-0879</td><td rowspan="4">shBRAF (+ Dox)</td><td rowspan="4">shBRAF (- Dox)</td><td>2%</td><td>1.77874</td><td>99.9%</td><td>3</td></tr><tr><td>15%</td><td>0.23717</td><td>84.6%</td><td>6</td></tr><tr><td>28%</td><td>0.12705</td><td>81.2%</td><td>19</td></tr><tr><td>40%</td><td>0.08894</td><td>80.4%</td><td>38</td></tr><tr><td rowspan="4">shCRAF (+ Dox)</td><td rowspan="4">shCRAF (- Dox)</td><td>2%</td><td>4.97629</td><td>99.9%</td><td>3</td></tr><tr><td>15%</td><td>0.66351</td><td>99.9%</td><td>3</td></tr><tr><td>28%</td><td>0.35545</td><td>88.0%</td><td>3</td></tr><tr><td>40%</td><td>0.24881</td><td>80.9%</td><td>5</td></tr><tr><td rowspan="8">PLX4720</td><td rowspan="4">shBRAF (+ Dox)</td><td rowspan="4">shBRAF (- Dox)</td><td>2%</td><td>3.13815</td><td>99.9%</td><td>3</td></tr><tr><td>15%</td><td>0.41841</td><td>96.2%</td><td>3</td></tr><tr><td>28%</td><td>0.22415</td><td>86.2%</td><td>7</td></tr><tr><td>40%</td><td>0.15690</td><td>82.9%</td><td>13</td></tr><tr><td rowspan="4">shCRAF (+ Dox)</td><td rowspan="4">shCRAF (- Dox)</td><td>2%</td><td>18.2081</td><td>99.9%</td><td>3</td></tr><tr><td>15%</td><td>2.42775</td><td>99.9%</td><td>3</td></tr><tr><td>28%</td><td>1.30058</td><td>99.9%</td><td>3</td></tr><tr><td>40%</td><td>0.91040</td><td>99.9%</td><td>3</td></tr></tbody></table></table-wrap></p><list list-type="bullet"><list-item><p>Based on these power calculations, we will then run the experiment seven times. Each time we will quantify band intensity. We will determine the standard deviation of band intensity across the biological replicates and combine this with the reported value from the original study to simulate the original effect size. We will use this simulated effect size to determine the number of replicates necessary to reach a power of at least 80%. We will then perform additional replicates, if required, to ensure that the experiment has more than 80% power to detect the original effect.</p></list-item></list></sec></sec><sec id="s3-3"><title>Protocol 3</title><sec id="s3-3-1"><title>Summary of original data reported in Figure 4A</title><list list-type="bullet"><list-item><p>Summary of data:<list list-type="bullet"><list-item><p>Normalization was performed by dividing the BRAF-band intensity by the captured GST-CRAF band intensity.</p></list-item></list></p></list-item></list><p><table-wrap id="tblu9" position="anchor"><table frame="hsides" rules="groups"><tbody><tr><td colspan="3">Figure 4A; assumed number of biological replicates = 3</td></tr><tr><td>BRAF variant</td><td>Drug</td><td>Normalized BRAF band density</td></tr><tr><td>WT</td><td>DMSO</td><td>1</td></tr><tr><td>WT</td><td>AMP-PCP</td><td>0.2</td></tr><tr><td>WT</td><td>GDC-0879</td><td>2.7</td></tr><tr><td>WT</td><td>PLX4720</td><td>0.2</td></tr><tr><td>V600E</td><td>DMSO</td><td>1</td></tr><tr><td>V600E</td><td>AMP-PCP</td><td>1.4</td></tr><tr><td>V600E</td><td>GDC-0879</td><td>1.3</td></tr><tr><td>V600E</td><td>PLX4720</td><td>1.3</td></tr></tbody></table></table-wrap></p><p>The original data does not indicate the error associated with multiple biological replicates. To identify a suitable sample size, power calculations were performed using different levels of relative variance using the values quantified from the reported image as the mean. At each level of variance, the effect size was estimated and used to calculate the needed sample size to achieve at least 80% power with the indicated alpha error. The achieved power is reported.</p></sec><sec id="s3-3-2"><title>Test family</title><list list-type="bullet"><list-item><p>Two-tailed <italic>t</italic>-test: Difference from constant (one sample case), Bonferroniâs correction, alpha error = 0.00833.</p></list-item></list></sec><sec id="s3-3-3"><title>Power calculations</title><list list-type="bullet"><list-item><p>Performed with G*Power software, version 3.1.7 (<xref ref-type="bibr" rid="bib3">Faul et al., 2007</xref>).</p></list-item></list><p><table-wrap id="tblu10" position="anchor"><table frame="hsides" rules="groups"><thead><tr><th>Group 1 (constant)</th><th>Group 2</th><th>Variance <break/>estimate</th><th>Effect <break/>size <italic>d</italic></th><th>A priori <break/>power</th><th>Samples <break/>per group</th></tr></thead><tbody><tr><td rowspan="4">WT BRAF (DMSO)</td><td rowspan="4">WT BRAF (AMP-PCP)</td><td>2%</td><td>200.00</td><td>99.9%</td><td>3</td></tr><tr><td>15%</td><td>26.667</td><td>99.9%</td><td>3</td></tr><tr><td>28%</td><td>14.286</td><td>99.4%</td><td>3</td></tr><tr><td>40%</td><td>10.000</td><td>91.8%</td><td>3</td></tr><tr><td rowspan="4">WT BRAF (DMSO)</td><td rowspan="4">WT BRAF (GDC-0879)</td><td>2%</td><td>31.482</td><td>99.9%</td><td>3</td></tr><tr><td>15%</td><td>4.1975</td><td>84.2%</td><td>4</td></tr><tr><td>28%</td><td>2.2487</td><td>82.0%</td><td>6</td></tr><tr><td>40%</td><td>1.5741</td><td>84.7%</td><td>9</td></tr><tr><td rowspan="4">WT BRAF (DMSO)</td><td rowspan="4">WT BRAF (PLX4720)</td><td>2%</td><td>200.00</td><td>99.9%</td><td>3</td></tr><tr><td>15%</td><td>26.667</td><td>99.9%</td><td>3</td></tr><tr><td>28%</td><td>14.286</td><td>99.4%</td><td>3</td></tr><tr><td>40%</td><td>10.000</td><td>91.8%</td><td>3</td></tr><tr><td colspan="3">Sensitivity calculations</td><td>Detectable effect <break/>size <italic>d</italic></td><td>A prior <break/>power</td><td>Samples <break/>per group</td></tr><tr><td rowspan="4">BRAF<sup>V600E</sup> (DMSO)</td><td rowspan="4">BRAF<sup>V600E</sup> (AMP-PCP)</td><td>2%</td><td>8.0194</td><td>80.0%</td><td>3</td></tr><tr><td>15%</td><td>3.9581</td><td>80.0%</td><td>4</td></tr><tr><td>28%</td><td>2.1973</td><td>80.0%</td><td>6</td></tr><tr><td>40%</td><td>1.4917</td><td>80.0%</td><td>9</td></tr><tr><td rowspan="4">BRAF<sup>V600E</sup> (DMSO)</td><td rowspan="4">BRAF<sup>V600E</sup> (GDC-0879)</td><td>2%</td><td>8.0194</td><td>80.0%</td><td>3</td></tr><tr><td>15%</td><td>3.9581</td><td>80.0%</td><td>4</td></tr><tr><td>28%</td><td>2.1973</td><td>80.0%</td><td>6</td></tr><tr><td>40%</td><td>1.4917</td><td>80.0%</td><td>9</td></tr><tr><td rowspan="4">BRAF<sup>V600E</sup> (DMSO)</td><td rowspan="4">BRAF<sup>V600E</sup> (PLX4720)</td><td>2%</td><td>8.0194</td><td>80.0%</td><td>3</td></tr><tr><td>15%</td><td>3.9581</td><td>80.0%</td><td>4</td></tr><tr><td>28%</td><td>2.1973</td><td>80.0%</td><td>6</td></tr><tr><td>40%</td><td>1.4917</td><td>80.0%</td><td>9</td></tr></tbody></table></table-wrap></p><list list-type="bullet"><list-item><p>Based on these power calculations, we will then run the experiment six times. Each time we will quantify band intensity. We will determine the standard deviation of band intensity across the biological replicates and combine this with the reported value from the original study to simulate the original effect size. We will use this simulated effect size to determine the number of replicates necessary to reach a power of at least 80%. We will then perform additional replicates, if required, to ensure that the experiment has more than 80% power to detect the original effect.</p></list-item></list></sec></sec></sec></body><back><ack id="ack"><title>Acknowledgements</title><p>The Reproducibility Project: Cancer Biology core team would like to thank the original authors, in particular Shiva Malek, for generously sharing critical information as well as reagents to ensure the fidelity and quality of this replication attempt. We thank Courtney Soderberg at the Center for Open Science for assistance with statistical analyses and Catherine Sutter at Kinexus Bioinformatics and Stephen Williams at the Center for Open Science for review and helpful comment on the manuscript. We would also like to thank the following companies for generously donating reagents to the Reproducibility Project: Cancer Biology; American Type Culture Collection (ATCC), Applied Biological Materials, BioLegend, Charles River Laboratories, Corning Incorporated, DDC Medical, EMD Millipore, Harlan Laboratories, LI-COR Biosciences, Mirus Bio, Novus Biologicals, Sigma-Aldrich, and System Biosciences (SBI).</p></ack><sec id="s4" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="conflict" id="conf1"><p>AB: Shakti Bioresearch is a Science Exchange associated lab.</p></fn><fn fn-type="conflict" id="conf2"><p>The other authors declare that no competing interests exist.</p></fn><fn fn-type="conflict" id="conf3"><p>BW: Biotechnology Research and Education Program is a Science Exchange associated lab.</p></fn><fn fn-type="conflict" id="conf4"><p>JK: Biotechnology Research and Education Program is a Science Exchange associated lab.</p></fn><fn fn-type="conflict" id="conf5"><p>RP:CB: EI, FT, JL, and NP are employed by and hold shares in Science Exchange Inc.</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>AB, Drafting or revising the article</p></fn><fn fn-type="con" id="con2"><p>SP, Drafting or revising the article</p></fn><fn fn-type="con" id="con3"><p>BW, Drafting or revising the article</p></fn><fn fn-type="con" id="con4"><p>JK, Drafting or revising the article</p></fn><fn fn-type="con" id="con5"><p>NM, Drafting or revising the article</p></fn><fn fn-type="con" id="con6"><p>RP:CB, Conception and design; Drafting or revising the article</p></fn></fn-group></sec><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carnahan</surname><given-names>J</given-names></name><name><surname>Beltran</surname><given-names>PJ</given-names></name><name><surname>Babij</surname><given-names>C</given-names></name><name><surname>Le</surname><given-names>Q</given-names></name><name><surname>Rose</surname><given-names>MJ</given-names></name><name><surname>Vonderfecht</surname><given-names>S</given-names></name><name><surname>Kim</surname><given-names>JL</given-names></name><name><surname>Smith</surname><given-names>AL</given-names></name><name><surname>Nagapudi</surname><given-names>K</given-names></name><name><surname>Broome</surname><given-names>MA</given-names></name><name><surname>Fernando</surname><given-names>M</given-names></name><name><surname>Kha</surname><given-names>H</given-names></name><name><surname>Belmontes</surname><given-names>B</given-names></name><name><surname>Radinsky</surname><given-names>R</given-names></name><name><surname>Kendall</surname><given-names>R</given-names></name><name><surname>Burgess</surname><given-names>TL</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Selective and potent raf inhibitors paradoxically stimulate normal cell proliferation and tumor growth</article-title><source>Molecular Cancer Therapeutics</source><volume>9</volume><fpage>2399</fpage><lpage>2410</lpage><pub-id pub-id-type="doi">10.1158/1535-7163.MCT-10-0181</pub-id></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Errington</surname><given-names>TM</given-names></name><name><surname>Iorns</surname><given-names>E</given-names></name><name><surname>Gunn</surname><given-names>W</given-names></name><name><surname>Tan</surname><given-names>FE</given-names></name><name><surname>Lomax</surname><given-names>J</given-names></name><name><surname>Nosek</surname><given-names>BA</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>An open investigation of the reproducibility of cancer biology research</article-title><source>eLife</source><volume>3</volume><pub-id pub-id-type="doi">10.7554/eLife.04333</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Faul</surname><given-names>F</given-names></name><name><surname>Erdfelder</surname><given-names>E</given-names></name><name><surname>Lang</surname><given-names>A-G</given-names></name><name><surname>Buchner</surname><given-names>A</given-names></name></person-group><year iso-8601-date="2007">2007</year><article-title>G*power 3: a flexible statistical power analysis program for the social, behavioral, and biomedical sciences</article-title><source>Behavior Research Methods</source><volume>39</volume><fpage>175</fpage><lpage>191</lpage><pub-id pub-id-type="doi">10.3758/BF03193146</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Halaban</surname><given-names>R</given-names></name><name><surname>Zhang</surname><given-names>W</given-names></name><name><surname>Bacchiocchi</surname><given-names>A</given-names></name><name><surname>Cheng</surname><given-names>E</given-names></name><name><surname>Parisi</surname><given-names>F</given-names></name><name><surname>Ariyan</surname><given-names>S</given-names></name><name><surname>Krauthammer</surname><given-names>M</given-names></name><name><surname>McCusker</surname><given-names>JP</given-names></name><name><surname>Kluger</surname><given-names>Y</given-names></name><name><surname>Sznol</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>PLX4032, a selective BRAFV600E kinase inhibitor, activates the ERK pathway and enhances cell migration and proliferation of BRAFWT melanoma cells</article-title><source>Pigment Cell &amp; Melanoma Research</source><volume>23</volume><fpage>190</fpage><lpage>200</lpage><pub-id pub-id-type="doi">10.1111/j.1755-148X.2010.00685.x</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hall-Jackson</surname><given-names>CA</given-names></name><name><surname>Eyers</surname><given-names>PA</given-names></name><name><surname>Cohen</surname><given-names>P</given-names></name><name><surname>Goedert</surname><given-names>M</given-names></name><name><surname>Tom Boyle</surname><given-names>F</given-names></name><name><surname>Hewitt</surname><given-names>N</given-names></name><name><surname>Plant</surname><given-names>H</given-names></name><name><surname>Hedge</surname><given-names>P</given-names></name></person-group><year iso-8601-date="1999">1999a</year><article-title>Paradoxical activation of raf by a novel raf inhibitor</article-title><source>Chemistry &amp; Biology</source><volume>6</volume><fpage>559</fpage><lpage>568</lpage><pub-id pub-id-type="doi">10.1016/S1074-5521(99)80088-X</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hall-Jackson</surname><given-names>CA</given-names></name><name><surname>Goedert</surname><given-names>M</given-names></name><name><surname>Hedge</surname><given-names>P</given-names></name><name><surname>Cohen</surname><given-names>P</given-names></name></person-group><year iso-8601-date="1999">1999b</year><article-title>Effect of SBâ203580 on the activity of c-raf in vitro and in vivo</article-title><source>Oncogene</source><volume>18</volume><fpage>2047</fpage><lpage>2054</lpage><pub-id pub-id-type="doi">10.1038/sj.onc.1202603</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hatzivassiliou</surname><given-names>G</given-names></name><name><surname>Song</surname><given-names>K</given-names></name><name><surname>Yen</surname><given-names>I</given-names></name><name><surname>Brandhuber</surname><given-names>BJ</given-names></name><name><surname>Anderson</surname><given-names>DJ</given-names></name><name><surname>Alvarado</surname><given-names>R</given-names></name><name><surname>Ludlam</surname><given-names>MJC</given-names></name><name><surname>Stokoe</surname><given-names>D</given-names></name><name><surname>Gloor</surname><given-names>SL</given-names></name><name><surname>Vigers</surname><given-names>G</given-names></name><name><surname>Morales</surname><given-names>T</given-names></name><name><surname>Aliagas</surname><given-names>I</given-names></name><name><surname>Liu</surname><given-names>B</given-names></name><name><surname>Sideris</surname><given-names>S</given-names></name><name><surname>Hoeflich</surname><given-names>KP</given-names></name><name><surname>Jaiswal</surname><given-names>BS</given-names></name><name><surname>Seshagiri</surname><given-names>S</given-names></name><name><surname>Koeppen</surname><given-names>H</given-names></name><name><surname>Belvin</surname><given-names>M</given-names></name><name><surname>Friedman</surname><given-names>LS</given-names></name><name><surname>Malek</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth</article-title><source>Nature</source><volume>464</volume><fpage>431</fpage><lpage>435</lpage><pub-id pub-id-type="doi">10.1038/nature08833</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heidorn</surname><given-names>SJ</given-names></name><name><surname>Milagre</surname><given-names>C</given-names></name><name><surname>Whittaker</surname><given-names>S</given-names></name><name><surname>Nourry</surname><given-names>A</given-names></name><name><surname>Niculescu-Duvas</surname><given-names>I</given-names></name><name><surname>Dhomen</surname><given-names>N</given-names></name><name><surname>Hussain</surname><given-names>J</given-names></name><name><surname>Reis-Filho</surname><given-names>JS</given-names></name><name><surname>Springer</surname><given-names>CJ</given-names></name><name><surname>Pritchard</surname><given-names>C</given-names></name><name><surname>Marais</surname><given-names>R</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Kinase-dead BRAF and oncogenic RAS cooperate to drive tumor progression through CRAF</article-title><source>Cell</source><volume>140</volume><fpage>209</fpage><lpage>221</lpage><pub-id pub-id-type="doi">10.1016/j.cell.2009.12.040</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoeflich</surname><given-names>KP</given-names></name><name><surname>Gray</surname><given-names>DC</given-names></name><name><surname>Eby</surname><given-names>MT</given-names></name><name><surname>Tien</surname><given-names>JY</given-names></name><name><surname>Wong</surname><given-names>L</given-names></name><name><surname>Bower</surname><given-names>J</given-names></name><name><surname>Gogineni</surname><given-names>A</given-names></name><name><surname>Zha</surname><given-names>J</given-names></name><name><surname>Cole</surname><given-names>MJ</given-names></name><name><surname>Stern</surname><given-names>HM</given-names></name><name><surname>Murray</surname><given-names>LJ</given-names></name><name><surname>Davis</surname><given-names>DP</given-names></name><name><surname>Seshagiri</surname><given-names>S</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Oncogenic BRAF is required for tumor growth and maintenance in melanoma models</article-title><source>Cancer Research</source><volume>66</volume><fpage>999</fpage><lpage>1006</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-05-2720</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hoeflich</surname><given-names>KP</given-names></name><name><surname>Herter</surname><given-names>S</given-names></name><name><surname>Tien</surname><given-names>J</given-names></name><name><surname>Wong</surname><given-names>L</given-names></name><name><surname>Berry</surname><given-names>L</given-names></name><name><surname>Chan</surname><given-names>J</given-names></name><name><surname>O'Brien</surname><given-names>C</given-names></name><name><surname>Modrusan</surname><given-names>Z</given-names></name><name><surname>Seshagiri</surname><given-names>S</given-names></name><name><surname>Lackner</surname><given-names>M</given-names></name><name><surname>Stern</surname><given-names>H</given-names></name><name><surname>Choo</surname><given-names>E</given-names></name><name><surname>Murray</surname><given-names>L</given-names></name><name><surname>Friedman</surname><given-names>LS</given-names></name><name><surname>Belvin</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Antitumor efficacy of the novel RAF inhibitor GDC-0879 is predicted by BRAFV600E mutational status and sustained extracellular signal-regulated Kinase/Mitogen-activated protein kinase pathway suppression</article-title><source>Cancer Research</source><volume>69</volume><fpage>3042</fpage><lpage>3051</lpage><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-08-3563</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Joseph</surname><given-names>EW</given-names></name><name><surname>Pratilas</surname><given-names>CA</given-names></name><name><surname>Poulikakos</surname><given-names>PI</given-names></name><name><surname>Tadi</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Taylor</surname><given-names>BS</given-names></name><name><surname>Halilovic</surname><given-names>E</given-names></name><name><surname>Persaud</surname><given-names>Y</given-names></name><name><surname>Xing</surname><given-names>F</given-names></name><name><surname>Viale</surname><given-names>A</given-names></name><name><surname>Tsai</surname><given-names>J</given-names></name><name><surname>Chapman</surname><given-names>PB</given-names></name><name><surname>Bollag</surname><given-names>G</given-names></name><name><surname>Solit</surname><given-names>DB</given-names></name><name><surname>Rosen</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>The RAF inhibitor PLX4032 inhibits ERK signaling and tumor cell proliferation in a V600E BRAF-selective manner</article-title><source>Proceedings of the National Academy of Sciences of the United States ofÂ America</source><volume>107</volume><fpage>14903</fpage><lpage>14908</lpage><pub-id pub-id-type="doi">10.1073/pnas.1008990107</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaplan</surname><given-names>FM</given-names></name><name><surname>Shao</surname><given-names>Y</given-names></name><name><surname>Mayberry</surname><given-names>MM</given-names></name><name><surname>Aplin</surname><given-names>AE</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Hyperactivation of MEKâERK1/2 signaling and resistance to apoptosis induced by the oncogenic b-RAF inhibitor, PLX4720, in mutant n-RAS melanoma cells</article-title><source>Oncogene</source><volume>30</volume><fpage>366</fpage><lpage>371</lpage><pub-id pub-id-type="doi">10.1038/onc.2010.408</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lee</surname><given-names>JT</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Brafford</surname><given-names>PA</given-names></name><name><surname>van den Eijnden</surname><given-names>M</given-names></name><name><surname>Halloran</surname><given-names>MB</given-names></name><name><surname>Sproesser</surname><given-names>K</given-names></name><name><surname>Haass</surname><given-names>NK</given-names></name><name><surname>Smalley</surname><given-names>KSM</given-names></name><name><surname>Tsai</surname><given-names>J</given-names></name><name><surname>Bollag</surname><given-names>G</given-names></name><name><surname>Herlyn</surname><given-names>M</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>PLX4032, a potent inhibitor of the b-raf V600E oncogene, selectively inhibits V600E-positive melanomas</article-title><source>Pigment Cell &amp; Melanoma Research</source><volume>23</volume><fpage>820</fpage><lpage>827</lpage><pub-id pub-id-type="doi">10.1111/j.1755-148X.2010.00763.x</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Poulikakos</surname><given-names>PI</given-names></name><name><surname>Zhang</surname><given-names>C</given-names></name><name><surname>Bollag</surname><given-names>G</given-names></name><name><surname>Shokat</surname><given-names>KM</given-names></name><name><surname>Rosen</surname><given-names>N</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>RAF inhibitors transactivate RAF dimers and ERK signalling in cells with wild-type BRAF</article-title><source>Nature</source><volume>464</volume><fpage>427</fpage><lpage>430</lpage><pub-id pub-id-type="doi">10.1038/nature08902</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Poulikakos</surname><given-names>PI</given-names></name><name><surname>Persaud</surname><given-names>Y</given-names></name><name><surname>Janakiraman</surname><given-names>M</given-names></name><name><surname>Kong</surname><given-names>X</given-names></name><name><surname>Ng</surname><given-names>C</given-names></name><name><surname>Moriceau</surname><given-names>G</given-names></name><name><surname>Shi</surname><given-names>H</given-names></name><name><surname>Atefi</surname><given-names>M</given-names></name><name><surname>Titz</surname><given-names>B</given-names></name><name><surname>Gabay</surname><given-names>MT</given-names></name><name><surname>Salton</surname><given-names>M</given-names></name><name><surname>Dahlman</surname><given-names>KB</given-names></name><name><surname>Tadi</surname><given-names>M</given-names></name><name><surname>Wargo</surname><given-names>JA</given-names></name><name><surname>Flaherty</surname><given-names>KT</given-names></name><name><surname>Kelley</surname><given-names>MC</given-names></name><name><surname>Misteli</surname><given-names>T</given-names></name><name><surname>Chapman</surname><given-names>PB</given-names></name><name><surname>Sosman</surname><given-names>JA</given-names></name><name><surname>Graeber</surname><given-names>TG</given-names></name><name><surname>Ribas</surname><given-names>A</given-names></name><name><surname>Lo</surname><given-names>RS</given-names></name><name><surname>Rosen</surname><given-names>N</given-names></name><name><surname>Solit</surname><given-names>DB</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>RAF inhibitor resistance is mediated by dimerization of aberrantly spliced BRAF(V600E)</article-title><source>Nature</source><volume>480</volume><fpage>387</fpage><lpage>390</lpage><pub-id pub-id-type="doi">10.1038/nature10662</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><collab>RÂ Core Team</collab></person-group><year iso-8601-date="2015">2015</year><article-title>R: a language and environment for statistical computing</article-title><source>R Foundation for Statistical Computing</source><uri xlink:href="http://www.R-project.org/">http://www.R-project.org/</uri></element-citation></ref></ref-list></back><sub-article article-type="article-commentary" id="SA1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.09976.002</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Davis</surname><given-names>Roger</given-names></name><role>Reviewing editor</role><aff id="aff6"><institution>Howard Hughes Medical Institute &amp; University of Massachusetts Medical School</institution>, <country>United States</country></aff></contrib></contrib-group></front-stub><body><boxed-text><p>In the interests of transparency, eLife includes the editorial decision letter and accompanying author responses. A lightly edited version of the letter sent to the authors after peer review is shown, indicating the most substantive concerns; minor comments are not usually included.</p></boxed-text><p>Thank you for submitting your work entitled &quot;Registered Report: RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth&quot; for peer review at <italic>eLife</italic>. Your submission has been favorably evaluated by Sean Morrison (Senior editor) and five reviewers, one of whom is a member of our Board of Reviewing Editors.</p><p>The reviewers have discussed the reviews with one another and the Reviewing editor has drafted this decision to help you prepare a revised submission.</p><p>This is a proposal to replicate a study by Malek and co-workers that demonstrated a role for Raf inhibitors to regulate CRAF/BRAF dimerization, activate the MAPK pathway, and increase tumor growth. The conclusions of this study have been widely accepted in the field. Nevertheless, this replication study is worthwhile. Three experiments will be replicated: Figure 1A, 2A and 2B.</p><p>There are two major concerns with the proposed replication study:</p><p>1) The restriction of the analysis to the PLX drug in each study. The authors should examine both the GDC-0879 and PLX-4720 drugs because the binding modes of these molecules are different.</p><p>2) As noted in the Registered Report Introduction, paradoxical RAF activation was described previously. The advance provided by the Nature paper was to identify a mechanism. The proposed replication studies (Figure 1A, 2A and 2B) do not really address the mechanistic conclusions of the paper. Consequently, the registered report should be expanded, for example â to include data showing drug-induced CRAF/BRAF dimerization (Figure 4A).</p><p>Additional comments:</p><p>A) The authors state that GDC-0879 and PLX-4720 have similar effects; however, as described in this paper and other work, these 2 compounds have very different binding modes to BRAF based on the structural studies described by Hatzivassiliou et al. This results in different functional effects as shown in Figure 2C and Figures 4A-C. For instance, the PLX-4720 molecule exhibited significantly less CRAF activation compared to GDC-0879, exhibited far less BRAF/CRAF dimerization, and overall had a weaker effect on paradoxical activation compared to GDC-0879 (requiring much higher doses of drug). Based on these significant differences, both drugs should be used to replicate the study.</p><p>B) No information is provided as to how the cell viability dose response (EC<sub>50</sub>) data will be fit. The data presented in Figure 1A reports an absolute EC<sub>50</sub> value and not a relative EC<sub>50</sub>. Also the highest dose of drug tested was 20 Î¼M and compounds which are shown at 20 Î¼M simply did not reach &gt;50% inhibition at the highest dose tested (20 Î¼M). This is apparent in Supplementary Figure 2 where the highest dose of GDC-0879 tested is 20 Î¼M and little effect is seen at that dose. Hence it is more accurate to compare EC<sub>50</sub> values in BRAF-WT cell lines selected to EC<sub>50</sub>&gt;20 Î¼M rather than the absolute 20 Î¼M value listed in the subsection âPower calculationsâ. Also as described in point 1, GDC-0879 should also be used in these studies for appropriate comparisons.</p><p>C) The authors propose starting dosing PLX-4720 in the cellular viability studies at 160 Î¼M; however, this compound is has decreased solubility in media or water. In order to conduct such a study, the authors need to first demonstrate that PLX-4720 is soluble in the media tested at this dose. The authors also do not provide information on whether the compound dilutions are conducted in DMSO first and then media is added. Due to solubility issues, the compound should first be serially diluted in DMSO and then media added, ensuring again the final DMSO concentration is not &gt;0.2%.</p><p>D) The cellular viability experiments are being conducted in 96-well plates (16,000 cells per well) and not 384-well plates and the seeding densities selected (14,000 cells per well) are not optimized. The authors need to identify optimal seeding densities for each given cell line ensuring that over the 4-day period of time the cells are in a logarithmic growth phase. The growth rates of cell lines will vary depending on both the media used as well as differences in serum lots, incubator temperature and other effects.</p><p>E) For Protocols 2 and 3: Again both PLX-4720 and GDC-0879 should be included when replicating these data given the different mechanisms of these inhibitors. As can be seen in Figure 2B, the data with these 2 compounds are not identical. The outcome of this experiment is also highly dependent on the degree of BRAF or CRAF knockdown upon Dox treatment. In order to appropriately replicate the results, the authors first need to ensure that with 2 mg/ml dox after 3 days BRAF and CRAF is depleted to similar levels as that shown in Figure 2B. If they are not, the authors need to optimize conditions further to ensure that the degree of BRAF and CRAF depletion is similar. The stable sh-inducible knockdown cell lines are pools and not clonal and hence optimization of knockdown conditions will be required as growth conditions will vary in a different laboratory with different lots of doxycyclin, serum, etc. Moreover, total MEK should be utilized to normalize pMEK levels for data analysis. Protein loading should be confirmed using actin and not BRAF or CRAF protein levels, especially given the experiment involves depleting cells of BRAF and CRAF.</p><p>F) As the variance increases, the sample size calculated increases â for example, the estimated sample size increases from 11 to 13 to 17 when the variance increases from 15% to 28% to 40%. Where do the investigators plan to stop their assumed variance and select a sample size? Please clarify.</p><p>G) Just before Protocol 2 description, the authors say that they will perform additional replicates to ensure that the experiment has more than 80% power. This gives the impression that the authors will continue to add more samples until they reach statistical significance. Please clarify.</p></body></sub-article><sub-article article-type="reply" id="SA2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.09976.003</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><p><italic>This is a proposal to replicate a study by Malek and co-workers that demonstrated a role for Raf inhibitors to regulate CRAF/BRAF dimerization, activate the MAPK pathway, and increase tumor growth. The conclusions of this study have been widely accepted in the field. Nevertheless, this replication study is worthwhile. Three experiments will be replicated: Figure 1A, 2A and 2B.</italic></p><p><italic>There are two major concerns with the proposed replication study: 1) The restriction of the analysis to the PLX drug in each study. The authors should examine both the GDC-0879 and PLX-4720 drugs because the binding modes of these molecules are different.</italic>We agree that both drugs should be added to the planned replication. The revised manuscript includes both compounds.</p><p><italic>2) As noted in the Registered Report Introduction, paradoxical RAF activation was described previously. The advance provided by the Nature paper was to identify a mechanism. The proposed replication studies (Figure 1A, 2A and 2B) do not really address the mechanistic conclusions of the paper. Consequently, the registered report should be expanded, for example</italic> â</p><p><italic>to include data showing drug-induced CRAF/BRAF dimerization (Figure 4A).</italic>We agree and have included Figure 4A in the revised manuscript. We are also removing Figure 2A from the replication attempt.</p><p><italic>Additional comments: A) The authors state that GDC-0879 and PLX-4720 have similar effects; however, as described in this paper and other work, these 2 compounds have very different binding modes to BRAF based on the structural studies described by Hatzivassiliou et al. This results in different functional effects as shown in Figure 2C and Figures 4A-C. For instance, the PLX-4720 molecule exhibited significantly less CRAF activation compared to GDC-0879, exhibited far less BRAF/CRAF dimerization, and overall had a weaker effect on paradoxical activation compared to GDC-0879 (requiring much higher doses of drug). Based on these significant differences, both drugs should be used to replicate the study.</italic></p><p>We agree that both drugs should be added to the planned replication. The revised manuscript includes both compounds.</p><p><italic>B) No information is provided as to how the cell viability dose response (EC<sub>50</sub>) data will be fit. The data presented in Figure 1A reports an absolute EC<sub>50</sub> value and not a relative EC<sub>50</sub>. Also the highest dose of drug tested was 20 Î¼M and compounds which are shown at 20 Î¼M simply did not reach &gt;50% inhibition at the highest dose tested (20 Î¼M). This is apparent in Supplementary Figure 2 where the highest dose of GDC-0879 tested is 20 Î¼M and little effect is seen at that dose. Hence it is more accurate to compare EC<sub>50</sub> values in BRAF-WT cell lines selected to EC<sub>50</sub>&gt;20 Î¼M rather than the absolute 20 Î¼M value listed in the subsection âPower calculationsâ. Also as described in point 1, GDC-0879 should also be used in these studies for appropriate comparisons.</italic>Thank you for raising these important points. It was not clear from the original paper if the EC<sub>50</sub> values were absolute or relative. Additionally, we have included how the EC<sub>50</sub> value will be determined: specifically, vehicle treated cells define 100% viability and the media-only wells define 0% viability, with the absolute EC<sub>50</sub> calculated as the concentration at which the curve crosses 50% viability when the top (100%) and baseline (0%) are held constant when fitting the four-parameter curve.</p><p>We agree that the values for PLX4720 and GDC-0879 are above 20 ÂµM for RAF<sup>WT</sup>/RAS<sup>WT</sup> and RAS<sup>MUTANT</sup> cell lines, however the concentration at which they do reach 50% inhibition is unknown (or not possible). The initial approach was to use 20 ÂµM as a conservative estimate of what that value might be. However, as it is unlikely to be reached without additional complications, as raised by the next comment (c) below, we are reframing the approach to perform the cellular viability experiments. We will perform the experiment exactly as originally reported. If a curve is unable to be fit, as was the case for the original report, the EC<sub>50</sub> will be reported as &gt;20 ÂµM. Only EC<sub>50</sub> values that can be accurately estimated will be reported and compared to the original reported values.</p><p>Finally, we have included the GDC-0879 compound in the revised manuscript.</p><p><italic>C) The authors propose starting dosing PLX-4720 in the cellular viability studies at 160 Î¼M; however, this compound is has decreased solubility in media or water. In order to conduct such a study, the authors need to first demonstrate that PLX-4720 is soluble in the media tested at this dose. The authors also do not provide information on whether the compound dilutions are conducted in DMSO first and then media is added. Due to solubility issues, the compound should first be serially diluted in DMSO and then media added, ensuring again the final DMSO concentration is not &gt;0.2%.</italic>Thank you for raising this important point. First, we have removed any additional concentrations that were used in the original assay in the revised manuscript. As a result, this will potentially lead to reporting EC<sub>50</sub> values as &gt;20 ÂµM, or &lt;0.078 ÂµM, similar to Hatzivasiliou et al., 2010. Only EC<sub>50</sub> values that can be accurately estimated will be reported and compared to the original reported values. Second, we have clarified the methodology to reflect how the compound dilutions are conducted first in DMSO and then media is added as described in Hoeflich et al., 2009, which was referenced in Hatzivassiliou et al., 2010.</p><p><italic>D) The cellular viability experiments are being conducted in 96-well plates (16,000 cells per well) and not 384-well plates and the seeding densities selected (14,000 cells per well) are not optimized. The authors need to identify optimal seeding densities for each given cell line ensuring that over the 4-day period of time the cells are in a logarithmic growth phase. The growth rates of cell lines will vary depending on both the media used as well as differences in serum lots, incubator temperature and other effects.</italic>We agree and have added an optimization protocol that will identify the seeding density of each cell to ensure the cells are in a logarithmic growth phase at the end of the time period. The results of the optimization protocol will define the seeding density used in the cellular viability experiments with the compounds.</p><p><italic>E) For Protocols 2 and 3: Again both PLX-4720 and GDC-0879 should be included when replicating these data given the different mechanisms of these inhibitors. As can be seen in Figure 2B, the data with these 2 compounds are not identical. The outcome of this experiment is also highly dependent on the degree of BRAF or CRAF knockdown upon Dox treatment. In order to appropriately replicate the results, the authors first need to ensure that with 2 mg/ml dox after 3 days BRAF and CRAF is depleted to similar levels as that shown in Figure 2B. If they are not, the authors need to optimize conditions further to ensure that the degree of BRAF and CRAF depletion is similar. The stable sh-inducible knockdown cell lines are pools and not clonal and hence optimization of knockdown conditions will be required as growth conditions will vary in a different laboratory with different lots of doxycyclin, serum, etc. Moreover, total MEK should be utilized to normalize pMEK levels for data analysis. Protein loading should be confirmed using actin and not BRAF or CRAF protein levels, especially given the experiment involves depleting cells of BRAF and CRAF.</italic></p><p>We agree that both drugs should be added to the planned replication. The revised manuscript includes both compounds. We also agree and have included an optimization step in the protocol for inducing knockdown of BRAF and CRAF by Dox treatment. A range of dox will be used to determine if 2 mg/ml dox is sufficient to knockdown BRAF and CRAF to levels similar to what was reported. If necessary, the concentration of dox will be adjusted prior to conducting the experiment.</p><p>We have pMEK levels normalized to total MEK, which is the DV used in the statistical analysis.</p><p>We agree that BRAF and CRAF are not ideal loading controls and have included actin as an additional measure not included in the original report.</p><p> <italic>F) As the variance increases, the sample size calculated increases</italic> â</p><p><italic>for example, the estimated sample size increases from 11 to 13 to 17 when the variance increases from 15% to 28% to 40%. Where do the investigators plan to stop their assumed variance and select a sample size? Please clarify.</italic>At the beginning of each protocol the starting sample size is defined (for each group), as well as at the end of each power calculation section. The range of variance is used to provide some guidance about the anticipated scope of the effort. Because we do not know the variance in the originally reported result, or what variance the replication might obtain, this approach provides a way to select an appropriate starting point, and thus minimum sample size. As stated at the end of each power calculation we will then use the variation from the minimum sample to perform a power calculation in order to identify if more samples are needed. This is further explained in response to the question below.</p><p><italic>G) Just before Protocol 2 description, the authors say that they will perform additional replicates to ensure that the experiment has more than 80% power. This gives the impression that the authors will continue to add more samples until they reach statistical significance. Please clarify.</italic></p><p>In order to perform a proper power calculation to determine minimum sample size, both the difference between means and variance estimates are needed. Because we do not have the original observed variance for Figure 2B, we have performed power calculations on a range of potential effect sizes (using the originally reported âmeanâ values and a range of variances to calculate Cohenâs <italic>d</italic>). This method acts as a guide for selecting a starting, minimum, sample size. After performing this minimum, pre-defined sample size we will use the variance from these replication samples together with the means from the original report to determine if additional biological replicates are needed. The additional samples will not be added until statistical significance is reached for the replication attempt, but rather additional samples will be added until the estimated original effect size (calculated using the originally reported âmeanâ value and the replication variance) can be detected with at least 80% power.</p></body></sub-article></article>